新疆寒燥型慢性阻塞性肺疾病的系统研究
|
摘要
目的：
选择中医药治疗COPD的常用治法,在运用系统评价和Meta分析确定中医药治疗COPD有效和安全的基础上,开展基于流行病学调查的新疆COPD和基于文献研究的内地COPD中医发病特点的对比研究,揭示新疆COPD的中医证型分布特点,找到特殊证型。在此基础上建立新疆寒燥型COPD动物模型,并从实验层面揭示寒燥型COPD的生物学基础,为COPD的方域化防治提供借鉴和参考。
方法：
利用系统评价和Meta分析的方法评价小青龙汤治疗COPD发作期和中医贴敷治疗COPD稳定期的疗效性和安全性；利用中医证候流行病学调查的方法揭示新疆COPD的发病特点,并将其和基于文献的内地COPD的发病特点进行对比研究,揭示新疆COPD的特殊证型。基于病因模拟-慢性应激-生物表征-药物反证的思路,利用气管滴注弹性蛋白酶结合熏烟90天建立COPD模型,在此基础上复合寒燥应激建立寒燥型COPD模型,通过肺功能、肺部病理观察和生物表征判断模型的成功建立,利用ELISA、Real-time PCR、Western-blot等方法检测模型内在病理生理状态,揭示寒燥型COPD的生物学基础。
结果：
1.小青龙汤联合西药内服可提高单纯西药治疗的有效率[MD=3.91,95%CI (2.50,6.12), P<0.00001],小青龙汤内服联合有创通气有效率优于单纯有创通气组[MD=3.48,95%CI (1.45,8.32), P=0.005];对于Pa02的改善小青龙汤联合西药内服优于单纯西药组[MD=7.55,95%CI (1.41,13.68), P=0.02];对于PaCO2的改善小青龙汤联合西药内服优于单纯西药组[MD=-7.11,95%CI (-9.89,-4.33),P<0.00001],小青龙汤内服联合有创通气优于单纯有创通气组[MD=-6.66,95%CI (-8.79,-4.54), P<0.00001];对于FEV1的改善小青龙汤联合西药内服优于单纯西药组[MD=6.97,95%CI (3.60,10.34), P<0.0001]。
2.所有加用中医贴敷组的有效率均优于未用中医贴敷组[MD=3.63,95%CI(2.84,4.65),P<0.00001]；对于FEV1,贴敷加西药组优于西药组[MD=0.29,95%CI(0.06,0.52),P=0.01]；对于FEV1/FVC,贴敷加中药优于中药组[MD=5.29,95%CI(2.52,8.07),P=0.0002]。
3.1)内地COPD总体症状中出现频次较多的是咳嗽(313,22.88%)、咳痰(204,14.91%)、气喘(124,9.06%)、喘息(120,8.77%)、气短(91,6.65%)、哮鸣音(54,3.95%)、胸闷(45,3.29%)、乏力(40,2.93%)、纳差(38,2.78%)、气促(36,2.63%)、自汗(28,2.05%)、易感冒(27,1.97%)；而新疆COPD出现频次较多的症状是气短(317次,4.43%),咳嗽(310例,4.33%),气喘(288,4.02%),咽干口干(259,3.62%),神疲乏力(244,3.41%),咳痰(235,3.28%),胸闷(227,3.17%),健忘(226,3.16%),汗出(211,2.95%),咽痒(207,2.89%),畏寒(206,2.88%),乏力(206,2.88%)；其中“燥”的表现(咽干、口干、鼻燥)为259例,占到全部调查病例的63%；“寒”的表现(恶风、畏寒、形寒怕冷、腰背冷痛、肢冷)为164例,占到全部调查病例的40%。“寒”兼“燥”的表现同时出现的为110例,占到全部调查病例的27%。内地COPD病位证素以肺(237,59.55%)、脾(81,20.35%)、肾(74,18.59%)为主,病性证素以痰(163,35.21%)、气虚(92,19.87%)、热(89,19.22%)、瘀(65,14.04%)、湿(14,3.02%)为主。证型主要以痰热蕴肺(69,19.77%)、痰瘀阻肺(43,12.32%)、肺脾气虚(33,9.46%)、肺。肾两虚(24,6.88%)、痰浊阻肺(20,5.73%)为主；新疆COPD病位证素以肺(287,61.46%),肾(142,30.41%),脾(38,8.14%)为主；病性为气虚(120,16.37%),寒(117,15.96%),阳虚(109,14.87%),痰(98,13.37%),阴虚(90,12.28%)为主。2)新疆和内地COPD患者相比舌质、舌苔和脉象总体分布不同。内地舌质瘀斑和舌质淡的多于新疆(P<0.01,P<0.05)；新疆舌质紫的则多于内地(P<0.01)；新疆舌质少津的构成比2.84%,内地舌质少津的构成比0.56%,新疆多于内地,但无统计学差异；内地患者舌质出现的胖、齿痕、绛、青则本次调查中新疆患者未见。内地黄苔和腻苔多于新疆(P<0.01),白苔和薄苔新疆多于内地(P<0.01),本次研究内地患者出现的浊苔、厚苔,本次调查新疆患者则未见。内地滑脉多于新疆(P<0.01),沉脉和弱脉多于新疆(P<0.05)；涩脉、紧脉新疆多于内地(P<0.05),浮脉和细脉新疆多于内地(P<0.01)；另外内地患者出现的无力、濡、结代、大脉本次调查新疆患者未见,迟脉则仅在新疆患者中出现,且占到7.93%。
4.1) COPD组及寒燥型COPD组肺部均有肺泡断裂融合、炎症细胞浸润和小支气管下平滑肌增厚现象,肺功能寒燥型COPD组的PEF、Ti、Te、EF50均高于对照组和COPD组,COPD组的Te和EF50高于空白对照组；2)COPD组及寒燥型COPD组体质量、体质量指数和Lee's指数均小于对照组(P<0.01),且寒燥型COPD组此三项指标均小于COPD组(P<0.01,P<0.05,P<0.01)。寒燥型COPD组每10g体质量每天进食量大于对照组和COPD组；3)寒燥型COPD组血清IL-1β含量高于空白对照组(P<0.05), IL-6、IL-8、TNF-α含量寒燥型COPD组均高于空白对照组(P<0.055、P<0.01、P<0.01), COPD组此三项指标也均高于空白对照组(P<0.01、P<0.05、P<0.05)；IL-10三组相比无统计学意义。寒燥型COPD组肺泡灌洗液IL-1p含量高于空白对照组(P<0.01), IL-6、IL-8、TNF-α含量寒燥型COPD组均高于空白对照组(P<0.01、P<0.01、 P<0.01), COPD组此三项指标也均高于空白对照组(P<0.05、P<0.05、P<0.05)；而且对于IL-6、IL-8寒燥型COPD组高于COPD组(P<0.05、P<0.05)；IL-10三组相比无统计学意义；4) MMP-2mRNA的表达量寒燥型COPD组和COPD组均高于空白对照组(P<0.01),且寒燥型COPD组高于COPD组(P<0.01)；对于MMP-9mRNA的表达量寒燥型COPD组和COPD组均高于空白对照组(P<0.01),且寒燥型COPD组高于COPD组(P<0.05)：而对于TIMP-1mRNA的表达量寒燥型COPD组和COPD组均高于空白对照组(P<0.01)；对于MMP-9mRNA/TIMP-lmRNA的比值寒燥型COPD组>COPD组>空白对照组；5)外周血中CD4+含量寒燥型COPD组低于空白对照组和COPD组(P<0.01)；CD8+含量寒燥型COPD组和COPD组均高于空白对照组(P<0.01),同时寒燥型COPD组高于COPD组(P<0.01)；CD4+/CD8比值寒燥型COPD组和COPD组均低于空白对照组(P<0.01),同时寒燥型COPD组低于COPD组(P<0.05)；6)对于AQP-5mRNA的表达量寒燥型COPD组和COPD组均低于空白对照组(P<0.01),且寒燥型COPD组低于COPD组(P<0.05)：对于MUC5ACmRNA的表达量寒燥型COPD组和COPD组均高于空白对照组(P<0.01),且寒燥型COPD组高于COPD组(P<0.01)；对于MUC5BmRNA的表达量寒燥型COPD组和COPD组均高于空白对照组(P<0.01),且寒燥型COPD组高于COPD组(P<0.05)；对于MUC5ACmRNA/MUC5BmRNA的比值COPD组<寒燥型COPD组<空白对照组；7)对于AQP-4、AQP-5蛋白的表达量寒燥型COPD组低于COPD组,COPD组低于空白对照组；对于MUC5AC、MUC5B的表达量寒燥型COPD组高于COPD组,COPD组高于空白对照组；8)大鼠模型肺部IL-8与TIMP-1、MMP-2、MUC5B相关,IL-8与MMP-9、MUC5AC密切相关,IL-8与AQP5负相关；IL-10与MMP-2、MMP-9负相关,IL-10与AQP5相关；TNF-a与MUC5AC密切相关；IL-6与TIMP-1相关,IL-6与AQP5负相关,IL-6与MMP-2、MMP-9、MUC5AC、MUC5B密切相关；TIMP-1与MMP-2、MMP-9相关；MMP-2与MMP-9、MUC5AC、MUC5B密切相关,MMP-2与AQP-5负相关；MMP-9与MUC5AC、MUC5B密切相关,MMP-9与AQP-5负相关；AQP5与MUC5AC、MUC5B负相关；MUC5AC与MUC5B密切相关。
结论：
1.发现中医内、外疗法治疗COPD均可显示出一定的疗效,但针对性不同,可与西医治疗实现优势互补。小青龙汤内服联合西医治疗COPD,可一定程度提高临床疗效,具体表现在增加有效率,提升Pa02、降低PaCO2上,同时可以某种程度提高患者FEVI。中医贴敷作为外治法如果联合内服药,则应根据患者表现选择相应的西药或中药联合。中医贴敷可以提高西药对FVC和FEV1改善的疗效,而中医贴敷不能提高中药对FEV1的改善程度。中医贴敷可提高中药对FEV1/FVC的改善,但对西药反而没有协同作用。
2.指出寒燥诱导和加剧了COPD的发病,是新疆COPD异于内地COPD发病、方域化发病的重要病因病机特点之一。体现在证型上则寒燥型是新疆COPD发病的特殊证型和多发证型之一,体现在病机上则该证型“局部燥,全身寒”、“内燥外寒”,体现在程度上则寒燥型属COPD的一个早期证型。内地COPD发病主要是痰、热、瘀为标,肺、脾、肾虚为本,痰、瘀、虚贯穿COPD发作期和缓解期的各个环节,是病机的主要环节所在,症状表现以咳嗽、咳痰、气喘、气短为主,临床治疗中应该注意祛痰、活血、补气药物的应用。而新疆COPD的发病则以气虚、寒、阳虚为主,肺、肾、脾虚为本,症状表现以气短、咳嗽、气喘、咽干口干、神疲乏力为主。临床治疗中应该注意祛痰止咳、温肺润燥、补气药的应用。
3.证实熏烟结合气道滴注弹性蛋白酶90天可以成功复制COPD模型,而在此基础上施加寒燥环境刺激建立新疆寒燥型COPD模型是可行的。寒燥型COPD模型表现为体型消瘦、体重下降、毛色黄无泽,气道内可闻及痰鸣音,体质量指数和Lee's指数减小,饮水、进食量增加且食物利用率低；PEF和EF50值降低、Ti、Te值增高。具有温肺润燥功效的中药止嗽散加减方对改善该病证的症状及肺功能有明显效果。但鉴于本证病机,法当辛开温润,不可过用温热而助燥伤津。
4.揭示寒燥通过COPD肺部AQP5mRNA和MUC5ACmRNA、MUC5BmRNA表达及其相应蛋白分泌的调节,降低了水通道蛋白的分泌,增加了黏蛋白的分泌,打破了水通道蛋白和黏蛋白的平衡,进而影响了气道黏液的功能状态,增加气道阻塞程度,促进以肺部炎症反应为主的肺部及全身炎症反应,扰乱了机体的免疫功能,导致机体肺气虚、卫外功能减弱,加重COPD的蛋白酶-抗蛋白酶失衡,进而促进和加重了COPD发病,可能是寒燥型COPD的重要生物学基础。
Objective:
To select common Chinese traditional medicine treatment for COPD. On the basis of effective and safe therapy on COPD, we use systematic review and meta-analysis to observe the characteristics between COPD patients in Xinjiang province based on epidemiological investigation and COPD patients in other provinces based on literatures. To observe the TCM syndrome distribution characteristics of COPD in Xinjiang and find the special pattern of syndrome. On this basis, to establish Xinjiang cold-dryness animal models of COPD. To provide evidences for revealing the biological mechanism of the cold-dryness COPD and regionalized prevention and treatment for COPD.
Method:
To evaluate the effect and safety of Xiaoqinglongtang for treatment of COPD and TCM sticking therapy for patients with stable COPD by using systematic reviews and meta-analysis. To reveal the characteristics of COPD in Xinjiang by using TCM syndrome epidemiological investigation, then to compare characteristics of COPD between them in Xinjiang and them in other provinces based on reports in literatures. Based on the method of etiologic simulation-chronic stress-biological phenotype-pharmacal disproof, to establish the COPD models by instilling elastinase into trachea and fumigating for90days. We determined the success of model construction by observing pulmonary function, pathological change and biological phenotypes. To detect the pathophysiological change by Elisa, real-time PCR and Western-blot.
Results:
1. the effective rate of combing western medicine and Xiaoqinglongtang is higher than only using western medicine [MD=3.91,95%CI (2.50,6.12), P<0.00001]. The effective rate in group of Xiaoqinglongtang combined with invasive ventilation is better than simply invasive ventilation group[MD=3.48,95%CI (1.45,8.32), P=0.005]. For the improvement of PaO2western medicine combined with Xiaoqinglongtang is superior to simple western medicine[MD=7.55,95%CI (1.41,13.68), P=0.02]; For the improvement of PaCO2western medicine combined with Xiaoqinglongtang [MD=-7.11,95%CI (-9.89,-4.33), P<0.00001] and Xiaoqinglongtang combined with invasive ventilation [MD=-6.66,95%CI (-8.79,-4.54), P<0.00001] are all superior to simple western medicine. For the improvement of FEV1, western medicine combined with Xiaoqinglongtang is superior to simple western medicine [MD=6.97,95%CI (3.60,10.34), P<0.0001].
2. The effective rates of COPD in the groups combined with external application are superior to the groups without external application[MD=3.63,95%CI (2.84,4.65), P<0.00001]; For improvement of FEV1, the group of western medicine combined with external application is superior to simple western medicine group. For improvement of FEV1/FVC, the group of TCM combined with external application is superior to simple TCM group [MD=5.29,95%CI (2.52,8.07),P=0.0002].
3.1) The most frequent symptom of COPD in other provinces are cough (313,22.88%), sputum (204,14.91%), asthma (124,9.06%) respite (120,8.77%), shortness of breath (91,6.65%), wheeze (54,3.95%), chest tightness (45,3.29%), fatigue (40,2.93%), anorexia (38,2.78%), shortness of breath (36,2.63%), spontaneous (28,2.05%), colds (27,1.97%); The most frequent symptom of COPD in Xinjiang are shortness of breath (317,4.43%), cough (310cases,4.33%), asthma (288,4.02%) throat, dry mouth (259,3.62%), lassitude (244,3.41%), sputum (235,3.28%), chest tightness (227,3.17%), forgetfulness (226,3.16%), sweating (211,2.95%), itchy throat (207,2.89%), chills (206,2.88%), fatigue (206,2.88%). The patients with the clinical manifestations "dry"(dryness of the mouth and throat, dry nose) are259cases, accounting for63%of in total cases under investigation; patients with the " cold " manifestations (evil wind chills, shaped cold, cold back, limbs) are164cases, accounted for40%of all investigated cases., patients with both symptoms are110cases, accounting for27%of all cases under investigation. The COPD symptoms in other provinces are slip known for lung (237,59.55%), spleen (81,20.35%), kidney (74,18.59%), disease nature elements sputum (163,35.21%), Qixu (92,19.87%), fever (89,19.22%), stasis (65,14.04%), wet (14,3.02%) the main. Syndrome type phlegm retention in the lung (69,19.77%), phlegm lung (43,12.32%), DLS (33,9.46%), lung and kidney deficiency (24,6.88%), phlegm blocking lungs (20,5.73%); The symptoms of COPD in Xinjiang are Slip known for lung (287,61.46%), kidney (142,30.41%), spleen (38,8.14%); disease deficiency (120,16.37%), cold (117,15.96%), Yangxu (109,14.87%), sputum (98,13.37%), Yinxu (90,12.28%).2) Tongue with cchymosis and pale in mainland was higher than in Xinjiang (P<0.01, P<0.05); tongue with purple in Xinjiang was higher than in mainland (P<0.01); constituent ratio of less of body fluid was2.84%in Xinjiang, but in mainland was0.56%, but made no difference; fat tongue, scalloped, purple, green tongue appearance in mainland but not in Xinjiang, yellow fur and greasy fur in mainland was higher than in Xinjiang (P<0.01); and white and thin fur in Xinjiang was high than in mainland (P<0.01); moss, thick fur appearance in mainland but not in Xinjiang, slippery pulse in mainland was higher than in Xinjiang (P<0.01); pulse astringent, tight pulse in Xinjiang were higher than in mainland (P<0.05); floating pulse and veinlets pulse in Xinjiang was higher than in mainland (P<0.01); weakness, soft pulse, intermittent pulse, large pulse just appearance in mailland; slow pulse will only occur in patients in Xinjiang, and accounted for7.93%.
4.1) Rats in COPD group, and cold-dry COPD group, we can observed the alveolar fracture fusion, infiltration of inflammatory cells and bronchial smooth muscle thickening, the lung function in cold-dryness COPD group, PEF, Ti, Te, EF50, were higher than them in COPD group, Te and EF50in COPD group were higher than them in control group;2) the body weight, body mass index, and Lee's index in COPD group and the cold-dryness COPD group were lower than them in control group (P<0.01), and these three parameters in cold-dryness COPD group were lower than them in COPD group (P<0.01, P<0.05, P <0.01). The daily food consumption per lOg body weight in cold-dryness COPD group was greater than it in control group and COPD group;3) Serum IL-1beta in cold-dryness COPD group was higher than that in control group (P<0.05), Serum IL-6, IL-8, TNF-alpha in cold-dryness COPD group were higher than them in control group (P<0.05, P<0.01, P<0.01), and these three parameters in COPD group were also higher than them in control group (P<0.01, P<0.05, P<0.05); the level of IL-10among three groups was not statistically different. The cold-dryness COPD BALF IL-lbeta content was higher than them in control group (P<0.01), IL-6, IL-8, TNF-alpha content in cold-dryness COPD group were higher than them in control group (P<0.01, P<0.01, P<0.01), and they were also higher in COPD group than them in the control group (P<0.05, P<0.05, P<0.05); and IL-6, IL-8was higher in cold-dryness COPD group than them in the COPD group (P <0.05, P<0.05); IL-10among three groups was not statistically different.4) MMP-2 mRNA expression level in cold-dryness COPD and COPD groups were higher than them in control group (P<0.01), and it was higher in cold-dryness COPD group than in the COPD group (P<0.01); MMP-9mRNA expression in both COPD and cold-dryness COPD groups were higher than it in control group (P<0.01), and it was higher in the cold-dryness COPD group than in the COPD group (P<0.05); TIMP-1mRNA expression level of cold dry COPD group and COPD group were higher than it control group (P<0.01); the ratio of MMP-9mRNA/TIMP-1mRNA was highest in cold-dryness COPD group (cold-dryness COPD group>COPD group>control group);5) peripheral blood CD4+in cold-dryness COPD group was lower than it in control group and COPD group (P <0.01); CD8+in cold-drynes COPD and COPD groups were higher than it in control group (P<0.01), while it was higher in cold-dryness COPD group than COPD group (P<0.01); ratio of CD4+/CD8+were lower in cold-dryness COPD and COPD groups (P<0.01), while the it was also lower in cold dry COPD group than in COPD group (P<0.05);6) The AQP-5mRNA of the expression in cold-dryness COPD and COPD groups were lower than it in control group (P<0.01), and it was lower in cold-dryness COPD group than it in the COPD group (P<0.05); MUC5AC expression in cold-dryness COPD and COPD groups were higher than it in control group (P<0.01), and it was higher in cold-dryness COPD group than it in the COPD group (P<0.01); MUC5BmRNA expression in cold-dryness COPD and COPD groups was higher than that in control group (P<0.01), and the cold dry COPD group was higher than the COPD group (P<0.05); ratio of MUC5ACmRNA/MUC5BmRNA was lowest in COPD group (COPD group Conclusion:
1. We found that the Chinese internal medicine and external application treatment of COPD were effective for COPD, but for different targets, it was complementary advantages combined with Western medicine treatment. Xiaoqinglongtang combined with Western medicine treatment of COPD may, to some extent, improve the clinical efficacy, specifically manifested in increased efficiency and improve PaO2, lower PaCO2, and it also can improve patients' FEV1. TCM sticking as external treatment combined with medicine should be based on the symptoms of patient. TCM sticking combined with Western medicine can improve the FVC and FEV1. However we did not observe th improvement of FEV1when combined the traditional Chinese medicine with Chinese medicine. TCM sticking combined with TCM improved FEV1/FVC, but there is no synergy with Western medicine.
2. We determined that the cold the dry induced and increased the incidence of COPD, which is the one of different characteristics from the COPD in other provinces. When concerned the pattern of syndrome,"cold-dryness" is the special permit and prevalent type of COPD in Xinjiang. When concerned the pathogenesis of the syndrome type, It characterized by " local dry, the whole body cold "and "within the dry, cold outside", when concerned the degree of COPD, cold-dryness is an early COPD syndrome type. Characteristics of COPD in othere provinces were heat, stasis as the phenotypes, deficiency of lung, spleen, kidney is the base; phlegm, blood stasis, virtual throughout the COPD exacerbation and remission of all aspects of the pathogenesis, the major symptoms are cough, sputum, wheezing, shortness of breath, phlegm, blood, qixu. Medicine application in clinical treatment should pay attention to those. Characteristics of COPD in Xinjiang are sputum, cloud, cold, dry as main phenotypes, and deficiency of lung, kidney, spleen as basis, shortness of breath, coughing, wheezing, dry throat, dry mouth, lassitude as main symptoms. Doctors should pay attention to cough expectorant, warm the lung dryness, drug application for qixu.in the clinical treatment of COPD.
3. We confirmed that fumes combined with Aikido infusion of elastase for90days can successfully construct the COPD model, and on the basis of which, cold-dry environ-ment can stimulate and establish Xinjiang cold-dryness COPD model. cold-dryness COPD models have some characters such as body weight loss, weight loss, disluster hair color, sputum in airway, decreases in body mass index and Lee's index, water and food consummation increased, but food utilization is lower; PEF and EF50reduced, Ti and Te value increased. Warm the lung moistening effect of traditional Chinese medicine Cough Powder plus or minus side to improve the certificates of disease symptoms and lung function had a marked effect. But in view of the pathogenesis of the card, when Acrid moist, not too warm and dry to help disability allowance
4. To reveal cold dry through the COPD lungs AQP5mRNA and MUC5AC, MUC5BmRNA expression and its corresponding regulation of protein secretion, reducing the water channel protein secretion, increasing mucin secretion, breaking the balance of aquaporin and mucin, thereby all these affect the functional status of the airway mucus, increase the degree of airway obstruction, promote the main pulmonary inflammatory response of the lungs and systemic inflammatory response, disrupt the body's immune function to cause lung qixu of the body, protection of the lung weakened, aggravate COPD protease-anti-protease imbalance, thus contributing to increased incidence of COPD, may be an important biological basis of cold-dryness COPD.
选择中医药治疗COPD的常用治法,在运用系统评价和Meta分析确定中医药治疗COPD有效和安全的基础上,开展基于流行病学调查的新疆COPD和基于文献研究的内地COPD中医发病特点的对比研究,揭示新疆COPD的中医证型分布特点,找到特殊证型。在此基础上建立新疆寒燥型COPD动物模型,并从实验层面揭示寒燥型COPD的生物学基础,为COPD的方域化防治提供借鉴和参考。
方法：
利用系统评价和Meta分析的方法评价小青龙汤治疗COPD发作期和中医贴敷治疗COPD稳定期的疗效性和安全性；利用中医证候流行病学调查的方法揭示新疆COPD的发病特点,并将其和基于文献的内地COPD的发病特点进行对比研究,揭示新疆COPD的特殊证型。基于病因模拟-慢性应激-生物表征-药物反证的思路,利用气管滴注弹性蛋白酶结合熏烟90天建立COPD模型,在此基础上复合寒燥应激建立寒燥型COPD模型,通过肺功能、肺部病理观察和生物表征判断模型的成功建立,利用ELISA、Real-time PCR、Western-blot等方法检测模型内在病理生理状态,揭示寒燥型COPD的生物学基础。
结果：
1.小青龙汤联合西药内服可提高单纯西药治疗的有效率[MD=3.91,95%CI (2.50,6.12), P<0.00001],小青龙汤内服联合有创通气有效率优于单纯有创通气组[MD=3.48,95%CI (1.45,8.32), P=0.005];对于Pa02的改善小青龙汤联合西药内服优于单纯西药组[MD=7.55,95%CI (1.41,13.68), P=0.02];对于PaCO2的改善小青龙汤联合西药内服优于单纯西药组[MD=-7.11,95%CI (-9.89,-4.33),P<0.00001],小青龙汤内服联合有创通气优于单纯有创通气组[MD=-6.66,95%CI (-8.79,-4.54), P<0.00001];对于FEV1的改善小青龙汤联合西药内服优于单纯西药组[MD=6.97,95%CI (3.60,10.34), P<0.0001]。
2.所有加用中医贴敷组的有效率均优于未用中医贴敷组[MD=3.63,95%CI(2.84,4.65),P<0.00001]；对于FEV1,贴敷加西药组优于西药组[MD=0.29,95%CI(0.06,0.52),P=0.01]；对于FEV1/FVC,贴敷加中药优于中药组[MD=5.29,95%CI(2.52,8.07),P=0.0002]。
3.1)内地COPD总体症状中出现频次较多的是咳嗽(313,22.88%)、咳痰(204,14.91%)、气喘(124,9.06%)、喘息(120,8.77%)、气短(91,6.65%)、哮鸣音(54,3.95%)、胸闷(45,3.29%)、乏力(40,2.93%)、纳差(38,2.78%)、气促(36,2.63%)、自汗(28,2.05%)、易感冒(27,1.97%)；而新疆COPD出现频次较多的症状是气短(317次,4.43%),咳嗽(310例,4.33%),气喘(288,4.02%),咽干口干(259,3.62%),神疲乏力(244,3.41%),咳痰(235,3.28%),胸闷(227,3.17%),健忘(226,3.16%),汗出(211,2.95%),咽痒(207,2.89%),畏寒(206,2.88%),乏力(206,2.88%)；其中“燥”的表现(咽干、口干、鼻燥)为259例,占到全部调查病例的63%；“寒”的表现(恶风、畏寒、形寒怕冷、腰背冷痛、肢冷)为164例,占到全部调查病例的40%。“寒”兼“燥”的表现同时出现的为110例,占到全部调查病例的27%。内地COPD病位证素以肺(237,59.55%)、脾(81,20.35%)、肾(74,18.59%)为主,病性证素以痰(163,35.21%)、气虚(92,19.87%)、热(89,19.22%)、瘀(65,14.04%)、湿(14,3.02%)为主。证型主要以痰热蕴肺(69,19.77%)、痰瘀阻肺(43,12.32%)、肺脾气虚(33,9.46%)、肺。肾两虚(24,6.88%)、痰浊阻肺(20,5.73%)为主；新疆COPD病位证素以肺(287,61.46%),肾(142,30.41%),脾(38,8.14%)为主；病性为气虚(120,16.37%),寒(117,15.96%),阳虚(109,14.87%),痰(98,13.37%),阴虚(90,12.28%)为主。2)新疆和内地COPD患者相比舌质、舌苔和脉象总体分布不同。内地舌质瘀斑和舌质淡的多于新疆(P<0.01,P<0.05)；新疆舌质紫的则多于内地(P<0.01)；新疆舌质少津的构成比2.84%,内地舌质少津的构成比0.56%,新疆多于内地,但无统计学差异；内地患者舌质出现的胖、齿痕、绛、青则本次调查中新疆患者未见。内地黄苔和腻苔多于新疆(P<0.01),白苔和薄苔新疆多于内地(P<0.01),本次研究内地患者出现的浊苔、厚苔,本次调查新疆患者则未见。内地滑脉多于新疆(P<0.01),沉脉和弱脉多于新疆(P<0.05)；涩脉、紧脉新疆多于内地(P<0.05),浮脉和细脉新疆多于内地(P<0.01)；另外内地患者出现的无力、濡、结代、大脉本次调查新疆患者未见,迟脉则仅在新疆患者中出现,且占到7.93%。
4.1) COPD组及寒燥型COPD组肺部均有肺泡断裂融合、炎症细胞浸润和小支气管下平滑肌增厚现象,肺功能寒燥型COPD组的PEF、Ti、Te、EF50均高于对照组和COPD组,COPD组的Te和EF50高于空白对照组；2)COPD组及寒燥型COPD组体质量、体质量指数和Lee's指数均小于对照组(P<0.01),且寒燥型COPD组此三项指标均小于COPD组(P<0.01,P<0.05,P<0.01)。寒燥型COPD组每10g体质量每天进食量大于对照组和COPD组；3)寒燥型COPD组血清IL-1β含量高于空白对照组(P<0.05), IL-6、IL-8、TNF-α含量寒燥型COPD组均高于空白对照组(P<0.055、P<0.01、P<0.01), COPD组此三项指标也均高于空白对照组(P<0.01、P<0.05、P<0.05)；IL-10三组相比无统计学意义。寒燥型COPD组肺泡灌洗液IL-1p含量高于空白对照组(P<0.01), IL-6、IL-8、TNF-α含量寒燥型COPD组均高于空白对照组(P<0.01、P<0.01、 P<0.01), COPD组此三项指标也均高于空白对照组(P<0.05、P<0.05、P<0.05)；而且对于IL-6、IL-8寒燥型COPD组高于COPD组(P<0.05、P<0.05)；IL-10三组相比无统计学意义；4) MMP-2mRNA的表达量寒燥型COPD组和COPD组均高于空白对照组(P<0.01),且寒燥型COPD组高于COPD组(P<0.01)；对于MMP-9mRNA的表达量寒燥型COPD组和COPD组均高于空白对照组(P<0.01),且寒燥型COPD组高于COPD组(P<0.05)：而对于TIMP-1mRNA的表达量寒燥型COPD组和COPD组均高于空白对照组(P<0.01)；对于MMP-9mRNA/TIMP-lmRNA的比值寒燥型COPD组>COPD组>空白对照组；5)外周血中CD4+含量寒燥型COPD组低于空白对照组和COPD组(P<0.01)；CD8+含量寒燥型COPD组和COPD组均高于空白对照组(P<0.01),同时寒燥型COPD组高于COPD组(P<0.01)；CD4+/CD8比值寒燥型COPD组和COPD组均低于空白对照组(P<0.01),同时寒燥型COPD组低于COPD组(P<0.05)；6)对于AQP-5mRNA的表达量寒燥型COPD组和COPD组均低于空白对照组(P<0.01),且寒燥型COPD组低于COPD组(P<0.05)：对于MUC5ACmRNA的表达量寒燥型COPD组和COPD组均高于空白对照组(P<0.01),且寒燥型COPD组高于COPD组(P<0.01)；对于MUC5BmRNA的表达量寒燥型COPD组和COPD组均高于空白对照组(P<0.01),且寒燥型COPD组高于COPD组(P<0.05)；对于MUC5ACmRNA/MUC5BmRNA的比值COPD组<寒燥型COPD组<空白对照组；7)对于AQP-4、AQP-5蛋白的表达量寒燥型COPD组低于COPD组,COPD组低于空白对照组；对于MUC5AC、MUC5B的表达量寒燥型COPD组高于COPD组,COPD组高于空白对照组；8)大鼠模型肺部IL-8与TIMP-1、MMP-2、MUC5B相关,IL-8与MMP-9、MUC5AC密切相关,IL-8与AQP5负相关；IL-10与MMP-2、MMP-9负相关,IL-10与AQP5相关；TNF-a与MUC5AC密切相关；IL-6与TIMP-1相关,IL-6与AQP5负相关,IL-6与MMP-2、MMP-9、MUC5AC、MUC5B密切相关；TIMP-1与MMP-2、MMP-9相关；MMP-2与MMP-9、MUC5AC、MUC5B密切相关,MMP-2与AQP-5负相关；MMP-9与MUC5AC、MUC5B密切相关,MMP-9与AQP-5负相关；AQP5与MUC5AC、MUC5B负相关；MUC5AC与MUC5B密切相关。
结论：
1.发现中医内、外疗法治疗COPD均可显示出一定的疗效,但针对性不同,可与西医治疗实现优势互补。小青龙汤内服联合西医治疗COPD,可一定程度提高临床疗效,具体表现在增加有效率,提升Pa02、降低PaCO2上,同时可以某种程度提高患者FEVI。中医贴敷作为外治法如果联合内服药,则应根据患者表现选择相应的西药或中药联合。中医贴敷可以提高西药对FVC和FEV1改善的疗效,而中医贴敷不能提高中药对FEV1的改善程度。中医贴敷可提高中药对FEV1/FVC的改善,但对西药反而没有协同作用。
2.指出寒燥诱导和加剧了COPD的发病,是新疆COPD异于内地COPD发病、方域化发病的重要病因病机特点之一。体现在证型上则寒燥型是新疆COPD发病的特殊证型和多发证型之一,体现在病机上则该证型“局部燥,全身寒”、“内燥外寒”,体现在程度上则寒燥型属COPD的一个早期证型。内地COPD发病主要是痰、热、瘀为标,肺、脾、肾虚为本,痰、瘀、虚贯穿COPD发作期和缓解期的各个环节,是病机的主要环节所在,症状表现以咳嗽、咳痰、气喘、气短为主,临床治疗中应该注意祛痰、活血、补气药物的应用。而新疆COPD的发病则以气虚、寒、阳虚为主,肺、肾、脾虚为本,症状表现以气短、咳嗽、气喘、咽干口干、神疲乏力为主。临床治疗中应该注意祛痰止咳、温肺润燥、补气药的应用。
3.证实熏烟结合气道滴注弹性蛋白酶90天可以成功复制COPD模型,而在此基础上施加寒燥环境刺激建立新疆寒燥型COPD模型是可行的。寒燥型COPD模型表现为体型消瘦、体重下降、毛色黄无泽,气道内可闻及痰鸣音,体质量指数和Lee's指数减小,饮水、进食量增加且食物利用率低；PEF和EF50值降低、Ti、Te值增高。具有温肺润燥功效的中药止嗽散加减方对改善该病证的症状及肺功能有明显效果。但鉴于本证病机,法当辛开温润,不可过用温热而助燥伤津。
4.揭示寒燥通过COPD肺部AQP5mRNA和MUC5ACmRNA、MUC5BmRNA表达及其相应蛋白分泌的调节,降低了水通道蛋白的分泌,增加了黏蛋白的分泌,打破了水通道蛋白和黏蛋白的平衡,进而影响了气道黏液的功能状态,增加气道阻塞程度,促进以肺部炎症反应为主的肺部及全身炎症反应,扰乱了机体的免疫功能,导致机体肺气虚、卫外功能减弱,加重COPD的蛋白酶-抗蛋白酶失衡,进而促进和加重了COPD发病,可能是寒燥型COPD的重要生物学基础。
Objective:
To select common Chinese traditional medicine treatment for COPD. On the basis of effective and safe therapy on COPD, we use systematic review and meta-analysis to observe the characteristics between COPD patients in Xinjiang province based on epidemiological investigation and COPD patients in other provinces based on literatures. To observe the TCM syndrome distribution characteristics of COPD in Xinjiang and find the special pattern of syndrome. On this basis, to establish Xinjiang cold-dryness animal models of COPD. To provide evidences for revealing the biological mechanism of the cold-dryness COPD and regionalized prevention and treatment for COPD.
Method:
To evaluate the effect and safety of Xiaoqinglongtang for treatment of COPD and TCM sticking therapy for patients with stable COPD by using systematic reviews and meta-analysis. To reveal the characteristics of COPD in Xinjiang by using TCM syndrome epidemiological investigation, then to compare characteristics of COPD between them in Xinjiang and them in other provinces based on reports in literatures. Based on the method of etiologic simulation-chronic stress-biological phenotype-pharmacal disproof, to establish the COPD models by instilling elastinase into trachea and fumigating for90days. We determined the success of model construction by observing pulmonary function, pathological change and biological phenotypes. To detect the pathophysiological change by Elisa, real-time PCR and Western-blot.
Results:
1. the effective rate of combing western medicine and Xiaoqinglongtang is higher than only using western medicine [MD=3.91,95%CI (2.50,6.12), P<0.00001]. The effective rate in group of Xiaoqinglongtang combined with invasive ventilation is better than simply invasive ventilation group[MD=3.48,95%CI (1.45,8.32), P=0.005]. For the improvement of PaO2western medicine combined with Xiaoqinglongtang is superior to simple western medicine[MD=7.55,95%CI (1.41,13.68), P=0.02]; For the improvement of PaCO2western medicine combined with Xiaoqinglongtang [MD=-7.11,95%CI (-9.89,-4.33), P<0.00001] and Xiaoqinglongtang combined with invasive ventilation [MD=-6.66,95%CI (-8.79,-4.54), P<0.00001] are all superior to simple western medicine. For the improvement of FEV1, western medicine combined with Xiaoqinglongtang is superior to simple western medicine [MD=6.97,95%CI (3.60,10.34), P<0.0001].
2. The effective rates of COPD in the groups combined with external application are superior to the groups without external application[MD=3.63,95%CI (2.84,4.65), P<0.00001]; For improvement of FEV1, the group of western medicine combined with external application is superior to simple western medicine group. For improvement of FEV1/FVC, the group of TCM combined with external application is superior to simple TCM group [MD=5.29,95%CI (2.52,8.07),P=0.0002].
3.1) The most frequent symptom of COPD in other provinces are cough (313,22.88%), sputum (204,14.91%), asthma (124,9.06%) respite (120,8.77%), shortness of breath (91,6.65%), wheeze (54,3.95%), chest tightness (45,3.29%), fatigue (40,2.93%), anorexia (38,2.78%), shortness of breath (36,2.63%), spontaneous (28,2.05%), colds (27,1.97%); The most frequent symptom of COPD in Xinjiang are shortness of breath (317,4.43%), cough (310cases,4.33%), asthma (288,4.02%) throat, dry mouth (259,3.62%), lassitude (244,3.41%), sputum (235,3.28%), chest tightness (227,3.17%), forgetfulness (226,3.16%), sweating (211,2.95%), itchy throat (207,2.89%), chills (206,2.88%), fatigue (206,2.88%). The patients with the clinical manifestations "dry"(dryness of the mouth and throat, dry nose) are259cases, accounting for63%of in total cases under investigation; patients with the " cold " manifestations (evil wind chills, shaped cold, cold back, limbs) are164cases, accounted for40%of all investigated cases., patients with both symptoms are110cases, accounting for27%of all cases under investigation. The COPD symptoms in other provinces are slip known for lung (237,59.55%), spleen (81,20.35%), kidney (74,18.59%), disease nature elements sputum (163,35.21%), Qixu (92,19.87%), fever (89,19.22%), stasis (65,14.04%), wet (14,3.02%) the main. Syndrome type phlegm retention in the lung (69,19.77%), phlegm lung (43,12.32%), DLS (33,9.46%), lung and kidney deficiency (24,6.88%), phlegm blocking lungs (20,5.73%); The symptoms of COPD in Xinjiang are Slip known for lung (287,61.46%), kidney (142,30.41%), spleen (38,8.14%); disease deficiency (120,16.37%), cold (117,15.96%), Yangxu (109,14.87%), sputum (98,13.37%), Yinxu (90,12.28%).2) Tongue with cchymosis and pale in mainland was higher than in Xinjiang (P<0.01, P<0.05); tongue with purple in Xinjiang was higher than in mainland (P<0.01); constituent ratio of less of body fluid was2.84%in Xinjiang, but in mainland was0.56%, but made no difference; fat tongue, scalloped, purple, green tongue appearance in mainland but not in Xinjiang, yellow fur and greasy fur in mainland was higher than in Xinjiang (P<0.01); and white and thin fur in Xinjiang was high than in mainland (P<0.01); moss, thick fur appearance in mainland but not in Xinjiang, slippery pulse in mainland was higher than in Xinjiang (P<0.01); pulse astringent, tight pulse in Xinjiang were higher than in mainland (P<0.05); floating pulse and veinlets pulse in Xinjiang was higher than in mainland (P<0.01); weakness, soft pulse, intermittent pulse, large pulse just appearance in mailland; slow pulse will only occur in patients in Xinjiang, and accounted for7.93%.
4.1) Rats in COPD group, and cold-dry COPD group, we can observed the alveolar fracture fusion, infiltration of inflammatory cells and bronchial smooth muscle thickening, the lung function in cold-dryness COPD group, PEF, Ti, Te, EF50, were higher than them in COPD group, Te and EF50in COPD group were higher than them in control group;2) the body weight, body mass index, and Lee's index in COPD group and the cold-dryness COPD group were lower than them in control group (P<0.01), and these three parameters in cold-dryness COPD group were lower than them in COPD group (P<0.01, P<0.05, P <0.01). The daily food consumption per lOg body weight in cold-dryness COPD group was greater than it in control group and COPD group;3) Serum IL-1beta in cold-dryness COPD group was higher than that in control group (P<0.05), Serum IL-6, IL-8, TNF-alpha in cold-dryness COPD group were higher than them in control group (P<0.05, P<0.01, P<0.01), and these three parameters in COPD group were also higher than them in control group (P<0.01, P<0.05, P<0.05); the level of IL-10among three groups was not statistically different. The cold-dryness COPD BALF IL-lbeta content was higher than them in control group (P<0.01), IL-6, IL-8, TNF-alpha content in cold-dryness COPD group were higher than them in control group (P<0.01, P<0.01, P<0.01), and they were also higher in COPD group than them in the control group (P<0.05, P<0.05, P<0.05); and IL-6, IL-8was higher in cold-dryness COPD group than them in the COPD group (P <0.05, P<0.05); IL-10among three groups was not statistically different.4) MMP-2 mRNA expression level in cold-dryness COPD and COPD groups were higher than them in control group (P<0.01), and it was higher in cold-dryness COPD group than in the COPD group (P<0.01); MMP-9mRNA expression in both COPD and cold-dryness COPD groups were higher than it in control group (P<0.01), and it was higher in the cold-dryness COPD group than in the COPD group (P<0.05); TIMP-1mRNA expression level of cold dry COPD group and COPD group were higher than it control group (P<0.01); the ratio of MMP-9mRNA/TIMP-1mRNA was highest in cold-dryness COPD group (cold-dryness COPD group>COPD group>control group);5) peripheral blood CD4+in cold-dryness COPD group was lower than it in control group and COPD group (P <0.01); CD8+in cold-drynes COPD and COPD groups were higher than it in control group (P<0.01), while it was higher in cold-dryness COPD group than COPD group (P<0.01); ratio of CD4+/CD8+were lower in cold-dryness COPD and COPD groups (P<0.01), while the it was also lower in cold dry COPD group than in COPD group (P<0.05);6) The AQP-5mRNA of the expression in cold-dryness COPD and COPD groups were lower than it in control group (P<0.01), and it was lower in cold-dryness COPD group than it in the COPD group (P<0.05); MUC5AC expression in cold-dryness COPD and COPD groups were higher than it in control group (P<0.01), and it was higher in cold-dryness COPD group than it in the COPD group (P<0.01); MUC5BmRNA expression in cold-dryness COPD and COPD groups was higher than that in control group (P<0.01), and the cold dry COPD group was higher than the COPD group (P<0.05); ratio of MUC5ACmRNA/MUC5BmRNA was lowest in COPD group (COPD group
1. We found that the Chinese internal medicine and external application treatment of COPD were effective for COPD, but for different targets, it was complementary advantages combined with Western medicine treatment. Xiaoqinglongtang combined with Western medicine treatment of COPD may, to some extent, improve the clinical efficacy, specifically manifested in increased efficiency and improve PaO2, lower PaCO2, and it also can improve patients' FEV1. TCM sticking as external treatment combined with medicine should be based on the symptoms of patient. TCM sticking combined with Western medicine can improve the FVC and FEV1. However we did not observe th improvement of FEV1when combined the traditional Chinese medicine with Chinese medicine. TCM sticking combined with TCM improved FEV1/FVC, but there is no synergy with Western medicine.
2. We determined that the cold the dry induced and increased the incidence of COPD, which is the one of different characteristics from the COPD in other provinces. When concerned the pattern of syndrome,"cold-dryness" is the special permit and prevalent type of COPD in Xinjiang. When concerned the pathogenesis of the syndrome type, It characterized by " local dry, the whole body cold "and "within the dry, cold outside", when concerned the degree of COPD, cold-dryness is an early COPD syndrome type. Characteristics of COPD in othere provinces were heat, stasis as the phenotypes, deficiency of lung, spleen, kidney is the base; phlegm, blood stasis, virtual throughout the COPD exacerbation and remission of all aspects of the pathogenesis, the major symptoms are cough, sputum, wheezing, shortness of breath, phlegm, blood, qixu. Medicine application in clinical treatment should pay attention to those. Characteristics of COPD in Xinjiang are sputum, cloud, cold, dry as main phenotypes, and deficiency of lung, kidney, spleen as basis, shortness of breath, coughing, wheezing, dry throat, dry mouth, lassitude as main symptoms. Doctors should pay attention to cough expectorant, warm the lung dryness, drug application for qixu.in the clinical treatment of COPD.
3. We confirmed that fumes combined with Aikido infusion of elastase for90days can successfully construct the COPD model, and on the basis of which, cold-dry environ-ment can stimulate and establish Xinjiang cold-dryness COPD model. cold-dryness COPD models have some characters such as body weight loss, weight loss, disluster hair color, sputum in airway, decreases in body mass index and Lee's index, water and food consummation increased, but food utilization is lower; PEF and EF50reduced, Ti and Te value increased. Warm the lung moistening effect of traditional Chinese medicine Cough Powder plus or minus side to improve the certificates of disease symptoms and lung function had a marked effect. But in view of the pathogenesis of the card, when Acrid moist, not too warm and dry to help disability allowance
4. To reveal cold dry through the COPD lungs AQP5mRNA and MUC5AC, MUC5BmRNA expression and its corresponding regulation of protein secretion, reducing the water channel protein secretion, increasing mucin secretion, breaking the balance of aquaporin and mucin, thereby all these affect the functional status of the airway mucus, increase the degree of airway obstruction, promote the main pulmonary inflammatory response of the lungs and systemic inflammatory response, disrupt the body's immune function to cause lung qixu of the body, protection of the lung weakened, aggravate COPD protease-anti-protease imbalance, thus contributing to increased incidence of COPD, may be an important biological basis of cold-dryness COPD.
引文
[1]Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Zhou Y, et al. Prevalence of chronic obstructive pulmonary disease in China:a large, population-based survey. Am J Respir Crit Care Med 2007; 176:753-760.
[2]加孜那·托哈依,胡晓婷,赵双锁,等.新疆和田农村地区60岁以上维吾尔族人群慢性阻塞性肺病的流行病学调查[J].新疆医科大学学报,2010,33(9)：1017-1010.
[3]Buist AS, Mcburnie MA, Vollmer WM, et al. International variation in the prevalence of COPD(the BOLD study):A population-based prevalence study[J]. The lancet,2007,370(9589):741-750.
[4]宋一平,崔德健,茅培英.COPD大鼠模型的建立及药物干预的影响[J].中华内科杂志,2000,39：712-714.
[5]宋一平,崔德健,茅培英,等.COPD大鼠模型气道重塑及生长因子的研究[J].中华结核和呼吸杂志,2001 24：283-287.
[6]许浒,熊密,黄庆华.细菌感染导致慢性阻塞性肺病大鼠模型的探讨[J].中华结核和呼吸杂志,1 999,22(12)：739-742.
[7]郭庭杰.COPD患者肺内的透明质酸水平增高与肺功能和局部炎症的相关性[J].国外医学内科学分册,2006,33(2)：92.
[8]Priiss-ustunA, Corvalan C. Preventing Disease trough Healthy Environments. Towards an Estimate of the Environment Burden of Disease[M]. Geneva:Word Health Organization,2006:19.
[9]岳海燕,申双和.呼吸道和心脑血管疾病与气象条件关系的研究进展[J].气象与环境学报,2009,25(2)：57.
[10]Donaldson GC, Seemungal T, Jeffries DJ, et al. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease[J]. Eur Respir J, 1999,13(4):844-849.
[11]梁剑辉.冬春须防寒—认识低温对COPD的影响[J].澳门医疗与健康,2010,11(1)：11.
[12]Koskela H, Pihlajamaki J, Pekkarinen H, et al. Effect of cold air on exercise capacity in COPD:increase or decrease. Chest.1998,113(6):1560-1565.
[13]Miravitlles M, Ferrer M, Pont A, et al. Effect if exacerbations on quality if life in patients with chronic obstructive pulmonary disease:a 2 year follow up study. Thorax.2004,59(5):387-395.
[14]De la lglesia martine F, pellicer vazquz C, Ramos polledo V, et al. Chronic obstructive pulmonary disease and the season of the year, Arch Bronchoneumol, 2000,36(2):84-89.
[15]Koskela HO. Cold air-provoked respiratory symptoms:the mechanisms and management][J]. Int J Circumpolar Health,2007,66(2):91-100.
[16]Davis MS, Malayer JR, Vandeventer L, et al. Cold weather exercise and airway cytokine expression [J]. j Appl Physiol,2005,98(6):2132-2136.
[17]阴俊,谈建国,竺丽明,等.不同地区慢性阻塞性肺病与气象因子相关性分析[J].气象科技,2007,35(6)：843.
[18]殷涛.外燥伤肺的分子机制研究[D].湖北中医药大学,2011：9.
[19]王剑,徐志伟,严灿,等.从黏液类物质病理改变探讨痰证机理[J].上海中医药杂志,2005,39(10)：44.
[20]Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways[J]. J Clin Invest,2002,109(5):571-577.
[21]陈淑靖,白春学.气道黏液中粘蛋白MUC5AC研究进展[J].中华结核和呼吸杂志,2007,30(6)：461-463.
[22]Middleton PG, Pollard KA, Wheatley JR. Hypertonic saline alters ion transport across the human airway epithelium [J]. Eur Respir J,2001,17(2):195-199.
[23]Mall MA. Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction:Lessons from mouse models[J]. J Aerosol Med Pulm Drug Deliv,2008, 21(1):13-24.
[24]Jayaraman S, Joo NS, Reitz B, et al. Submucosal gland secretions in airways from cystic fibrosis patients have normal Na+and pH but elevated viscosity. Proc Natl Acad Sci USA,2001,98:8119.
[25]National Institute for Clinical Excellence(NICE). Chronic obstructive pulmonary disease:national clinical guideline on management of chronic abstructive pulmonary disease in adults in primary and secondary care. Thorax 2004,59.
[26]Moretti M, Bottrighi P, Dallari R, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease:the EQUALIFE Study[J]. Drugs Exp Clin Res,2004,30(4):143-152.
[27]Fahy JV. Goblet cell and mucin gene abnormalities in asthma[J]. Chest,2002, 122(6 Suppl):320S.
[28]何燕霞,巨春荣,宋改芳,等.慢性阻塞性肺病大鼠气道炎症细胞及黏蛋白检测[J].郑州大学学报(医学版),2007,42(1)：126.
[29]杨宝学,赵雪俭.水通道蛋白的研究进展[J].中国病理生理杂志,2005,21(8)：1619-1622.
[30]SaadounS, PaPadoPou}05MC, Hara-ChikumaM, etal:ImPairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature,2005, 434:786-92,
[31]Ruiz-EderraJ, VerkmanAS:AquaPorin-l-feeilitatedkeratoCyte migration in cell culture and in vivo corneal wound healing models. ExPEye Res2009,89:159-65.
[32]Borok Z, Verkman A S. Lung edema clearance:20 years of progress invited review:role of aquaporin, water channels in fluid transport in lung and airways[J]. J Appl Physiol,2002,93:2199-2206
[33]Shen Y, W ang YL, Chen ZH, et al. Role of aquaporin 5 in antigen-induced airway inflammation and mucous hyperproduction in mice[J]. J Cell Mol Med,2011, 15(6):1355-1363.
[34]Caramori G, Di Gregorio C, Carlstedt I, et al. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease[J]. Histopathology, 2004,45(5):477-484.
[35]Wang K, Feng YL, Wen FQ, et al. Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease[J]. Acta Pharmacol Sin,2007,28(8):1166-1174.
[36]董春玲,鲁继荣,王桂芳,等.哮喘小鼠肺组织中水通道蛋白5和黏蛋白5AC的表达变化及其相关性研究[J].中国现代医学杂志,2007,(24)：2961-2965,2970.
[37]Chen Z, Zhu R, Bai L, et al. Downregulation of aquaporin 5 induced by vector-based short hairpin RNA and its effect on MUC5AC gene expression in human airway submucosal gland cells[J]. Respir Physiol Neurobiol,2006,152(2): 197-203.
[38]Jiao G, Li E, Yu R. Decreased expression of AQP1 and AQP5 in acute injured lung in rats[J]. Chin Med J(Engl),2002,115(7):963.
[39]Towne JE, Harrod KS, Krane CM, et al. Decreased expression of aquaporin (AQP) land AQP5in mouse lung after acute viral infection[J]. Am J Respir Cell Mol Biol, 2000,22:34-44.
[40]张子强,水通道蛋白5促进肺癌增殖迁移及参与肺上皮屏障的作用和机制研究[D].复旦大学,2010：89.
[41]孙忠民,朱柏,杨岚,等.AQP4在COPD支气管黏膜的表达及其与患者肺功能 起到黏膜炎症的相关性[J].西安交通大学学报,2008,29(2)：193-195.
[42]祝小惠,钟相根,李宇航,等.“通利大肠”对COPD大鼠AQPs mRNA表达的影响及与气道炎症相关性研究[J].中华中医药杂志,2010,25(12)：2246-2249.
[43]胡利群,丁建中.水通道蛋白与肺部疾病研究进展[J].长江大学学报：自科版医学版,2008,5(4)：83-86.
[44]张六通,丁建中,王明明,等.外燥对小鼠肺组织水通道蛋白5表达的影响及意义[J].湖北中医学院学报,2010,12(1)：3-5.
[45]丁建中,尚荣,张燕翔,等.水通道蛋白4在外燥小鼠肺组织表达的实验研究[J].长江大学学报(自然科学版)2010,7(3)：2.
[46]张六通,丁建中,李军川,等.外燥对小鼠肺组织水通道蛋白5表达的影响及意义[J].湖北中医学院学报,2010,12(1)：3-5.
[47]高振,李风森,哈木拉提·吾甫尔,杨剑.慢性阻塞性肺病中医证治用药的性味及归经规律研究[J].中医药杂志(台湾),2010,21(3,4)：143-148.
[48]李风森,同立宏,荆晶,等.穴位贴敷治疗慢性阻塞性肺病稳定期选穴及用药规律研究[J].中国中医药信息杂志,2012,19(6)：24-27.
[49]中华医学会呼吸病学分会·慢性阻塞性肺病(COPD)诊治规范(草案).中华结核和呼吸杂志,1997,20(4)：199-203.
[50]中华医学会呼吸病学分会慢性阻塞性肺病学组.慢性阻塞性肺病诊治指南.中华结核和呼吸杂志,2002,25(8)：453-460.
[51]中华医学会呼吸病学分会慢性阻塞性肺病组.慢性阻塞性肺病诊治指南(2007年修订版).中华结核和呼吸杂志,2007,1(30)：8.
[52]GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2006, http://goldcopd. com/index. 2007-01-22.
[53]韩萍.四逆汤合小青龙汤加减治疗AECOPD疗效观察.皖南医学院学报,2010,29(1)：54-56.
[54]任明智.小青龙汤对慢性阻塞性肺病急性加重期的临床疗效观察.中国实用医药,2012,7(7)：129-130.
[55]钱旭红.小青龙汤治疗慢性阻塞性肺病发作期30例疗效分析.中国医药科学,2011,1(18)：73+80.
[56]杨荣源,林燕凤,李际强.小青龙汤加减治疗慢性阻塞性肺病急性加重期临床观察.新中医,2009,41(1)：43-44.
[57]李军林.小青龙汤治疗慢性阻塞性肺病发作期39例临床观察.基层医学论坛,2011,15(28)：943-944.
[58]韩萍.附子理中汤合小青龙汤加减治疗慢性阻塞性肺病急性加重期疗效观察.中国中医急症,2011,20(5)：694-695.
[59]王东.加味小青龙汤治疗痰浊阻肺型COPD急性加重期的临床疗效观察.广州中医药大学,2011：11-18.
[60]谢加富,陈仕章,秦平祥,曹锐彬,朱少惠,李颂梅,陈美英,张艳.小青龙汤配合基础治疗对慢性阻塞性肺病患者血氧饱和度的影响.临床和实验医学杂志,2008,7(9)：5-6.
[61]邹交平.丹参注射液合小青龙汤加减治疗慢性阻塞性肺病急性发作32例.安徽中医临床杂志,1999,11(3)：172.
[62]李旭.小青龙汤治疗慢性阻塞性肺病急性加重期39例临床观察.中医临床研究,2011,3(23)：41-43.
[63]赵军,金英.小青龙汤合血府逐瘀汤用于慢性阻塞性肺病发作期40例疗效观察.贵阳中医学院学报,2007,29(5)：19-20.
[64]谢加富,曹锐彬,陈仕章,秦平祥,朱少惠,李颂梅,陈美英,张艳.小青龙合剂配合基础治疗对慢性阻塞性肺病患者排痰效果的影响.实用医学杂志,2009,25(1)：144-146.
[65]方灵云.小青龙汤治疗COPD38例观察.浙江临床医学,2003,5(3)：217.
[66]韦金荣.小青龙汤加味治疗肺心病疗效观察.中医临床研究,2010,2(16)：77.
[67]葛长胜,高翠,闫培清,张华.小青龙汤联合无创通气治疗慢性阻塞性肺病合并呼吸衰竭36例.实用中医内科杂志,2010,(7)：33-35.
[68]钟勇.小青龙汤结合无创通气治疗慢性阻塞性肺病急性加重期30例的临床研究.时珍国医国药,2010,21(7)：1836-1837.
[69]孔祥建.小青龙汤雾化吸入对COPD急性加重期呼吸功能及血气的影响.湖南中医杂志,2010,26(4)：19-20.
[70]徐新毅,周洵,刘炜,等.止咳平喘膏穴位敷贴配合西药治疗慢性阻塞性肺病36例临床研究[J].贵阳中医学院学报,2005,27(2)：38～40.
[71]郑彩霞,王洪刚,刘振安.穴位贴敷为主治疗慢性阻塞性肺病90例[J].中医研究,2005,18(10)：36～37.
[72]徐艳玲,赵克明,曲妮妮,等.中药涌泉穴位贴敷治疗慢性阻塞性肺病稳定期的临床研究[J].辽宁中医杂志,2008,35(7)：1055～1056.
[73]王海峰,李素云,王明航,等.中药穴位贴敷治疗慢性阻塞性肺病患者临床观察及免疫功能的影响[J].中华中医药学刊,2009,27(6)：1209～1211.
[74]关秋红,武维屏,田秀英,等.益气活血化痰贴防治慢性阻塞性肺病临床观察[J].中国中医药信息杂志,2009,16(11)：60～61.
[75]石克华,折哲,熊必丹,等.咳喘散穴位敷贴治疗慢性阻塞性肺病稳定期临床疗效观察[J].世界中西医结合杂志,2009,4(3)：195～197.
[76]朱晓龙.中药“穴位贴敷”治疗慢性阻塞性肺病肺肾气虚型患者临床疗效观察[D].贵阳中医学院,2010：19-26.
[77]阚竞.中药三伏贴治疗慢性阻塞性肺病稳定期(肺肾气虚型)的临床观察[D].湖北中医药大学,2010：3-11.
[78]刘斌,李英姿,黄大文.中药穴位敷贴对慢性阻塞性肺病免疫球蛋白及C反应蛋白的影响[J].湖北中医杂志,2010,32(12)：7～8.
[79]邓莉,徐艳玲.中药涌泉穴贴敷治疗慢性阻塞性肺病及护理[J].实用中医内科杂志,2010,25(3)：41～42.
[80]夏令琼,廖色青,梁云花,等.中药敷贴治疗慢性阻塞性肺病稳定期临床观察及护理[J].齐齐哈尔医学院学报,2010,31(16)：2657～2658.
[81]潘继红,黄玮.“伏九”穴位贴敷对慢性阻塞性肺病患者免疫功能影响的临床研究[J].中医药导报,2011,17(6)：68～70.
[82]谭光波,柏正平,胡学军.冬病夏治敷贴疗法对COPD稳定期患者生活质量的影响[C].全国中西医结合防治呼吸系统疾病学术研讨会论文集》浙江·杭州：2009：77-80.
[83]毕蓉蓉,张惠勇,耿佩华,等.冬病夏治穴位疗法对慢性阻塞性肺病患者肺通气功能的影响[J].上海中医药大学学报,2011,25(3)：32～35.
[84]杨耀忠,郭美珠,梁薇,等.穴位敷贴治疗慢性阻塞性肺病稳定期临床研究[J].辽宁中医杂志,2011,38(6)：1192～1194.
[85]王兰娣.中药穴位贴敷联合补肺益寿合剂治疗慢性阻塞性肺病71例[J].甘肃中医学院学报,2009,26(6)：33～35.
[86]王燕芳.补肺益肾方联合穴位贴敷对慢性阻塞性肺病稳定期的疗效评价及成本效果分析[D].河南中医学院,2010：8-25.
[87]张颖,高鹏飞,方忠宏,等.中药治疗慢性阻塞性肺病的疗效观察[J].上海中医药杂志,2004,38(6)：6～7.
[88]牟晓华,沈宁,邱梦茹.止咳平喘贴治疗慢性阻塞性肺病缓解期临床观察[J].中国中医药信息杂志,2009,16(12)：59～60.
[89]范春,周运海.三伏天穴位敷贴结合金水宝口服治疗肺肾两虚型COPD稳定期30例临床研究[J].江苏中医药,2011,43(7)：69～70.
[90]浦明之.穴位敷贴配合扶正胶囊治疗肺肾两虚型COPD稳定期疗效观察[J].山西中医,2010,26(4)：40～41.
[91]彭明松,龚新全,谢六安.中药穴位贴敷治疗慢性阻塞性肺病的临床观察[J]. 湖北中医杂志,2006,28(7)：44～45.
[92]宋昱晨.穴位贴敷与卡介苗素注射治疗稳定期慢性阻塞性肺病的疗效和免疫指标对比观察[J].浙江中医杂志,2008,43(8)：441-443.
[93]陈平,许光兰.益气补肺膏穴位敷贴治疗慢性阻塞性肺病缓解期33例[J].陕西中医,2009,30(8)：945～947.
[94]王海燕,郑连雪.穴位贴敷治疗慢性阻塞性肺病60例[J].中国中医药现代远程教育,2010,8(23)：33～34.
[95]郑菲,李国勤,边永君,等.内外合治法治疗慢性阻塞性肺病稳定期的疗效观察[J].中国中西医结合杂志,2010,30(4)：369～372.
[96]魏亚东,鱼涛,谢燕华,等.“冬病夏治”治疗慢性阻塞性肺病稳定期患者疗效观察[J].中华中医药杂志,201 1,26(2)：408～410.
[97]马敏敏,张惠勇,段晨霞,等.冬病夏治穴位疗法对稳定期脾肾阳虚型慢性阻塞性肺病患者肺功能及生存质量的影响[J].辽宁中医杂志2011,38(5)：923～927.
[98]李素云,李建生,余学庆,等.舒肺贴治疗慢性阻塞性肺病疗效观察[J].陕西中医,2009,30(4)：391～392.
[99]李国勤,王蕾,边永君,等.冬病夏治消喘膏穴位贴敷疗法治疗稳定期慢阻肺的多中心随机双盲安慰剂对照研究[C].中国北京：2010：152-157.
[100]Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias, dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA,1995,273(5):408-412.
[101]周铭心.西北燥证研究概述[J].上海中医药杂志,2005,39(11)：43-45.
[102]周仲英主编,中医内科学[M].北京：中国中医药出版社,2003.
[103]国家技术监督局.GB/T16751. 2-1997中医临床诊疗术语：证候部分[S].北京：中国标准出版社,1997.
[104]冷南方主编.中医证候辩治轨范[M].北京：人民卫生出版社：1889.
[105]李风森,高振.慢性阻塞性肺病寒燥型诊断标准(2011版)[J].新疆医科大学学报,2012,35(10)：1317,1322.
[106]北京中医学院中医系中医基础理论教研室编,濒湖脉学白话解[M].北京：人民卫生出版社,1973年第2版修订：69.
[107]北京中医学院中医系中医基础理论教研室编,濒湖脉学白话解[M].北京：人民卫生出版社,1973年第2版修订：49.
[108]张连文,袁世宏.隐结构模型与中医辨证研究[J].北京中医药大学学报,2006,29(6)：365-369.
[109]王天芳,张连文,赵燕,等.隐结构模型及其在中医证候研究中的应用[J].北京中医药大学学报,2009,32(8)：519-526.
[110]王洪图主编,普通高等教育中医类规划教材：《内经选读》[M].上海：上海科学技术出版社,1997：65.
[111]徐雯洁,王天芳,王智瑜,等.基于隐结构法的慢性阻塞性肺病稳定期常见证候要素研究[J]北京中医药大学学报,2011,34(2)：82-86.
[112]Kara M. Preparing nurses for tile global pandemic of chronic obstructive pulmonary disease[J]. J Nurs Scholarsh,2005,37(2):127-133.
[113]阚海东,陈秉衡,贾健.上海市大气污染与居民每日死亡关系的病例交叉研究[J].中华流行病学杂志2003,24(10)：864.
[114]李小芡,胡志,李守田,等.安徽农村不同居住环境对慢阻肺患病率的影响[J].中国农村卫生事业管理,2002,22(4)：46-48.
[115]孟紫强,胡敏,郭新彪,等.沙尘暴对人体健康影响的研究现状[J].中国公共卫生2003,19(4)：471.
[116]Kwaasi AA, ParharRS, al-Mohanna FA, etal. Aeroallergens and viable microbes in sandstorm dust, Potential triggers of allergic and nonallergic res Nonallergic respiratory ailments[J]. allergy,1998,53(3):255-265.
[117]李风森,高振,荆晶等.慢性阻塞性肺病寒燥型分布状况及临床特点[J],中国中医药信息杂志,2012,19(2)：1-4.
[118]Mahadeva R, Shapiro SD. Chronic obstructive pulmonary disease:experimental animal models of pulmonary emphysema[J]. Thorax,2002,57:908-914.
[119]宋小莲,王昌惠,白冲.脂多糖结合熏烟法和单纯熏烟法建立慢性阻塞性肺病大鼠模型的比较[J].第二军医大学学报,2010,31(3)：248.
[120]迟春花,何冰,汤秀英,等.烟草雾吸入导致慢阻肺机制的实验研究一大鼠Clara细胞结构及其分泌蛋白的变化[J].心肺血管病杂志,2000,19：224-227.
[121]Cendon SP, Battlehner C, Lorenzi Filho G, et al. Pulmonary emphysema induced by passive smoking:an experimental study in rats. Braz J Med Biol Res,1997, 30(10):1241-1247.
[122]曾祥伯,COPD模型大鼠骨骼肌细胞凋亡及Bcl-2、Bax表达的实验研究[D].中南大学,2008：4-9.
[123]孙圣华.TNF-α对COPD营养不良动物模型骨骼肌蛋白质分解代谢的影响及可能的机制[D].中南大学,2006：3-11.
[124]窦桂荣,林炳水,崔振环,等.TRI近交系大鼠不同鼠龄、体重、身长及尾长的动态变化[J].中国实验动物学杂志,1995,5(2)：88-90.
[125]何明,涂长春,黄起壬,等Lee's指数用于评价成年大鼠肥胖程度的探讨[J].中国临床药理学与治疗杂志,1997,2(3)：177-179.
[126]黄婷婷,邱小汕,沈振宇,等.孕期营养不良对子代大鼠胰岛素抵抗的影响[J].中华预防医学杂志,2004,38(3)：184.
[127]冉丕鑫,王辰,姚婉贞,等.体重指数与慢性阻塞性肺病及生活质量的关系[J].中华结核和呼吸杂志,2007,30(1)：18-22.
[128]顾宇彤,蔡映云,柳启沛,等.慢性阻塞性肺病缓解期患者营养状况及对呼吸肌力量的影响[J].中华内科杂志,1998,37(10)：685.
[129]林江涛.缓解期慢性阻塞性肺病患者的营养状态与营养治疗[J].中华结核和呼吸杂志,1996,19(5)：261.
[130]Celli B R, Cote C G, Marin J M, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease[J]. N Engl J Med,2004,350(10):1005-1012.
[131]马真,卓宋明,周路球,等.体重指数与慢性阻塞性肺病的相关性研究[J].现代预防医学,2011,38(12)：2418.
[132]王芸,陈霞.慢性阻塞性肺病急性发作期患者营养状况与预后相关性的临床观察[J].现代预防医学,2011,38(18)：3838.
[133]Kessler R, Faller M, Fourgaut G, et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir CritCare Med,1999,159(1):158-164
[134]Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1998,157(6 Ptl):1791-1797.
[135]Romain K, Michele F, GillesF, etal-Predictive factors ofhospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med,1999;159:158-64.
[136]SahebijamiH, SathianpitayakulE-Influence ofbodyweight on the severity of dyspnea in chronic obstructive pulmonary disease[J]. Am J Respir Care Med, 2000;161:886-90.
[137]Vibhuti A, Arif E, Deepak D, et al. Correlation of oxidative status with BMI and lung function in COPD. Clin Biochem,2007,40(13-14):958.
[138]夏廉博.医疗气象学：天气、气候对健康的影响[M].北京：知识出版社,1984：32-34.
[139]常静,张颖,毛兵,等.柴葛清热颗粒治疗急性上呼吸道感染风热证的双盲随 机对照临床试验[J].中西医结合学报,2007,5(2)：141-146.
[140]仝战旗,钱妍,林明雄,等.“防感1号”预防老年人反复上呼吸道感染的临床研究[J].中华医院感染学杂志,2006,16(9)：1004-1006.
[141]钱桂生.急性上呼吸道感染[J].高校保健医学研究与实践,2005,2(1)：4-5.
[142]Davis SS. Nasal vaccines[J]. Adv Drug Deliv Rev,2001,51(1-3):21-42.
[143]李风森,高振,荆晶,等.慢性阻塞性肺病寒燥型模型全身炎症反应状态研究[J].科技导报,2011,29(18)：65-68.
[144]黄河,慢性阻塞性肺病稳定期患者血清瘦素及IL-1β与营养状况、生活质量及肺功能关系的初步研究[D].山东大学,2006：24.
[145]邵洪波,吴厚生,倪赞明.SLE患者外周血单核细胞分泌IL-6和IgG的研究[J].中国免疫学杂志,1993,9(2)：121.
[146]侯静静,朱蕾.白介素-8与慢性阻塞性肺病[J].国外医学：呼吸系统分册,2005,25(6)：427-429.
[147]周立新,陈凤娥,张秀平,等.白细胞介素-10在慢性阻塞性肺病患者血清中的表达及意义[J].数理医药学杂志,2000,13(6)：499-500.
[148]Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med,1995;152:1666-1672.
[149]Finlay GA, O'Driscoll LR, Russell KJ, D'Arcy EM, Masterson JB, FitzGerald MX, O'Connor CM. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997; 156:240-247.
[150]Bode W., Fernandez-Catalan C., Grams F, et al. Insights into MMP-TIMP Interactions. Ann. NY Acad. Sci.,1999,878:73-91.
[151]Hautamaki, RD, Kobayashi, DK, Senior, RM Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997;277,2002-2004.
[152]Morris, DG, Huang, X, Kaminsky, N, et al Loss of integrin alpha(v)beta6-mediated TGFβ activation causes MMP-12 dependent emphysema. Nature 2003;22, 169-173.
[153]Imai, K, Dalal, SS, Chen, E, et al Human collagenase(matrix metalloproteinase-1) expression in the lung of patients with emphysema. Am J Respir Crit Care Med 2001;163,786-791.
[154]Russell, RE, Culpitt, SV, Dematos, C, et al Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002;26,602-609.
[155]Segura-Valdez, L, Pardo, A, Gaxiola, M, et al Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000; 117,684-694.
[156]Ohnishi, K, Takagi, M, Kurokawa, Y, et al Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998;78,1077-1087.
[157]Cataldo D, Munaut C, Noe A, et al MMP-2-and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2000; 123,259-267.
[158]Vignola, AM, Riccobono, L, Mirabella, A, et al Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998; 158,1945-1950.
[159]Culpitt, S, Rogers, D, Traves, S, et al Sputum matrix metalloproteases:comparison between chronic obstructive pulmonary disease and asthma. Respir Med 2005;99, 703-710.
[160]Vignola, AM, Paganin, F, Capieu, L, et al Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J 2004;24,910-917.
[161]Vernooy, JH, Lindeman, JH, Jacobs, JA, et al Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004; 126,1802-1810.
[162]Betsuyaku, T, Nishimura, M, Takeyabu, K, et al Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med 1999;159,1985-1991.
[163]Finlay, GA, O'Driscoll, LR, Russell, KJ Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997; 156,240-247.
[164]Vignola, AM, Paganin, F, Capieu, L, et al Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J 2004;24,910-917.
[165]Madri, JA, Graesser, D, Haas, T The roles of adhesion molecules and proteinases in lymphocyte transendothelial migration. Biochem Cell Biol 1996;74,749-757.
[166]Chung, A, Gao, Q, Kao, WJ Macrophage matrix metalloproteinase-2/-9 gene and protein expression following adhesion to ECM-derived multifunctional matrices via integrin complexation. Biomaterials 2007;28,285-298.
[167]Masumoto, K, de Rooij, D, Suita, S, et al Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases during normal human pulmonary development. Histopathology 2005;47,410-419.
[168]Johnson, S, Knox, A Autocrine production of matrix metalloproteinase-2 is required for human airway smooth muscle proliferation. Am J Physiol 1999;277,L1109-L1117.
[169]Imai K, DalalSS, Chen ES, et al. Human collagenase(matrix metalloproteinase-1) expression in the lungs of patients with emphysema[J]. Am J Respir Crit Care Med, 2001,163:786-791.
[170]辛建保,胡道松,向敏,等.基质金属蛋白酶在肺气肿兔肺组织中的表达[J].中华结核和呼吸杂志,1999,22(6)：364.
[171]Selman M, Montano M, Ramos C, et al. Tobacco smoke-induced lung emphysema in guinea pigs is associated with increased interstitial collagenase[J]. Am J Physiol[J].1996,271:L734-L743.
[172]D Armiento J, Dalal SS, Okada Y, et al. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema[J]. Cell,1992,71:955-961.
[173]Bosse M., Chakir J, Rouabhia M, et al. Serum matrix metalloproteinase-9:Tissue inhibitor of matelloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. AM J Respir Crit Care Med,1999,159:596-602.
[174]Antonio M, Viguola, Loredana Riccobono, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinanse-1 ratio correlates with airflow obstruction in asthma and chronic bronchitism[J]. Am J Respir Care Med.,1998,158:1945-1950.
[175]Jerome pugin, Marie-Claude Widmer, Sylvie Kossodo, et al. Human neutrophils secrete gelatinase B in citro and in vivo in response to endotoxin and proinflammation mediators[J]. Am J Respir Cell Mol Biol,1999,20:458-464.
[176]Sam Lim, Nicolas Roche, Brian G. Oliver, Waldo Mattos, et al. Balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 from alveolar macrophages in cigarette smokers[J]. Am J Respir Care Med.,2000,162:1355-1360.
[177]Lourdes Segura-Valdez, Annte Pardo, Miguel Gaxiola, et al. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD[J]. Chese,2000,117:684-694.
[178]Wang Z, Zheng T, Zhu Z, Homer RJ, Riese RJ, Chapman HA Jr, Shapiro SD, Elias JA. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med 2000;192:1587-1600.
[179]Wert SE, Yoshida M, LeVine AM, Ikegami M, Jones T, Ross GF, Fisher JH, Korfhagen TR, Whitsett JA. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc Natl Acad Sci USA 2000;97:5972-5977.
[180]Selman M, Cisneros-Lira J, Gaxiola M, Ramirez R, Kudlacz EM, Mitchell PG, Pardo A. Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in Guinea pigs. Chest 2003;123:1633-1641.
[181]Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Gera L, Tuder RM, Voelkel NF. Methylprednisolone causes matrix metalloproteinase-dependent emphysema in adult rats. Am J Respir Crit Care Med2003;167:1516-1521.
[182]Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, Shim TS, Kim SE, Lee YS, Lee SD. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med,2005;172:987-993.
[183]Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT. Matrix metal loproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998;78:1077-1087.
[184]Mao JT, Tashkin DP, Belloni PN, Baileyhealy I, Baratelli F, Roth MD. All-trans retinoic acid modulates the balance of matrix metallo-proteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. Chest 2003; 124:1724-1732.
[185]Beeh KM, Beier J, Kornmann O, Buhl R. Sputum matrix metallo-proteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 2003;97:634-639.
[186]Russell RE, Thorley A, Culpitt SV, Dodd S, Donnelly LE, Demattos C, Fitzgerald M, Barnes PJ. Alveolar macrophage-mediated elastolysis:roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol 2002;283:L867-L873.
[187]Montano M, Beccerril C, Ruiz V, Ramos C, Sansores RH, Gonzalez-Avila G. Matrix metalloproteinases activity in COPD associated with wood smoke. Chest 2004;125:466-472.
[188]Foronjy R, Nkyimbeng T, Wallace A, Thankachen J, Okada Y, Lemaitre V, D'Armiento J. Transgenic expression of matrix metalloproteinase-9causes adult-onset emphysema in mice associated with the loss of alveolar elastin. Am J Physiol Lung Cell Mol Physiol 2008;294:L1149-L1157.
[189]Murphy G, Docherty A. The matrix metalloproteinases and their inhibitors[J]. Am J Respir Cell Mol Biol,1992,7:120-125.
[190]Mautino G, Oliver N, Chanez P, et al. Increased release of matrix metallo-proteinases-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics[J]. Am J Respir Cell Mol Biol.1997,17(5):583-91.
[191]Yao PM, Lemjabbar H, Dortho mp, et al. Balance between MMP-9 and TIMP-1 expressed by human bronchial epithelial cells:relevance to asthma[J]. Ann N Y Acad Sci.1999,30;878:512-514.
[192]Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003;28:12-24.
[193]Bosse M., Chakir J, Rouabhia M, et al. Serum matrix metalloproteinase-9:Tissue inhibitor of matelloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. AM J Respir Crit Care Med,1999,159:596-602.
[194]Culpitt SV, Rogers DF, Traves SL, Barnes PJ, Donnelly LE:Sputum matrix metalloproteases:comparison between chronic obstructive pulmonary disease and asthma. Respir Med 2005,99:703-710.
[195]Vernooy JH, Lindeman JH, Jacobs JA, Hanemaaijer R, Wouters EF:Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004,126:1802-1810.
[196]高振,阿地力江,哈木拉提.吾甫尔.寒燥型证候模型免疫功能紊乱的研究[J].中华中医药杂志,2010,25(8)：1227.
[197]高振,胡汉华,刘莹莹,等.寒燥型证候模型下丘脑-垂体-肾上腺轴紊乱状态研究[J].中医杂志,2010,51(10)：929.
[198]高振,阿地力江·阿布力米提,哈木拉提·吾甫尔.干燥寒冷环境对小鼠生物表征的影响[J].科技导报,2008,26(14)：84-87.
[199]尚德阳.瘀血与骨质疏松症的关系研究[J].辽宁中医药大学学报,2008,10(9)：41.
[200]Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bonemineral density in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med,2004,70(12):1286-1293.
[201]Shane E, Silverberg SJ, Donovan D, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease[J]. Am J Med,1996,101(3):262-269.
[202]Iqbal F, Michaelson J, Thaler L, et al. Declining bone mass in men with chronic pulmonary disease:contribution of glucocorticoid treatment, body mass index, and gonadal function[J]. Chest,1999,116(6):1616-1624.
[203]Rifas L, Fausto A, Scott MJ, et al. Expression of metalloproteinase and tissue inhibitors of metalloproteinase in human osteoblast-like cells:differentiatiln is associated with repression of metalloproteinase biosynthesis[J]. Endocrinology, 1994,134(1):213-221.
[204]刘敬,许增禄,王计奎,等.绝经后骨质疏松I型胶原代谢的变化[J].解剖学报,2002,33(2)：166-169.
[205]Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease:molecular and cellular mechanisms. Eur Respir J 2003;22:672-688.
[206]钟南山.慢性阻塞性肺病在中国[J].中国实用内科杂志,2011,31(5)：321-322.
[207]Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD)Workshop Summary. Am J Respir Crit Care Med 2001;163:1256-1276.
[208]Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020:Global Burden of Disease Study. Lancet 1997;349:1498-1504.
[209]李风森,高振,荆晶,等.慢性阻塞性肺病西北寒燥正分布及临床特点[J].中国中医药信息杂志,2012,19(2)：22-24.
[210]Chrousos GP. Stress and disorders of the stress system[J]. Nat Rev Endocrinol, 2009,5(7):374-381.
[211]Finkelstein R, Ma HD, Ghezzo H, et al. Morphometry of small airways in smokers and its relationship to emphysema type and hyperresponsiveness. Am J Respir Crit Care Medl995;152:267-76.
[212]Majo J, Ghezzo H, Cosio MG Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J2001;17:946-53.
[213]O'Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis:inverse relationship of CD8+T lymphocytes with FEV1. Am J Respir Crit Care Med1997;155:852-7.
[214]Saetta M, Di Stefano A, Turato G, et al. CD8+T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:822-6.
[215]Turato G, Zuin R,miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease:relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med2002; 166:105-10
[216]Baraldo S, Turato G, Badin C, et al. Neutrophilic infiltration within the airway smooth muscle in patients with COPD. Thorax2004;59:308-12.
[217]Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-30.
[218]Lowin B, Hahne M, Mattmann C, et al. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994;370:650-2.
[219]Syriala H, Surcel HM, Ilonea J. Low CD4/CD8 Lymphocyte ratio in acute myocardial infauction[J]. Clin Exp Immunol,1991,83(2):326-328.
[220]Peralbo E, Alonso C, Solana R. Invariant NKT and NKT-like lymphocytes:two different T cell subsets that are differentially affected by ageing[J]. Exp Gerontol, 2007,42(8):703-708.
[221]Turato G, Zuin R,miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease:relationship with lung function and radiologic emphysema [J]. Am J Respir Crit Care Med,2002,166(1):105-110.
[222]Casio MG, Majo J. Inflammation of the airways and lung parenchy main COPD:role of T cells [J]. Chest,2002,121(5 supply):160-165.
[223]Saetta M, Stefan AD. CD8+T-Lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med.1998;157: 822-6.
[224]Turato G, Zuin R, Seatta M. Pathogenesis and pathology of COPD. Respiration, 2001;68(2):117-28.
[225]王可.COPD的粘液分泌机制研究[D].四川大学博士学位论文,2006：1.
[226]Williams OW, Sharafkhaneh A, Kim V, Dickey BF, Evans CM. Airway mucus:from production to secretion. Am J Respir Cell Mol Biol 2006;34:527-526.
[227]周向东,童瑾,兰箭.性阻塞性肺疾病患者气道粘蛋白分子表型的研究[J]中华结核和呼吸杂志,2002,7(25)：437-437.
[228]祝小惠,钟相根,李宇航,等.COPD大鼠AQPs mRNA表达及“从肠论治”干预作用[J].中华中医药学刊,2011,29(1)：39-41.
[229]Verkman AS. Aquaporin water channels and endothelial cell function[J]. J Anat 2002;200:617-27.
[230]蒋力生,叶明花校注.喻嘉言医学三书·医门法律[M]北京：中医古籍出版社,2004：507.
[1]王彦,吴红英,李德冠,等.三个品系小鼠的遗传检测[J].中国辐射卫生,2010,19(1)：19-20.
[2]Prtather R S, Hawley R J, Carter D B, et al. Transgenic swine for biomedicine and agriculture[J]. Theriogenology,2003,59(1):115-123.
[3]Plopper CQ Hyde DM. The non-human primate as a model for studying COPD and asthma[J]. Pulm Pharmacol Ther. 2008,21 (5):755-766.
[4]Cai C, Zhang H, LE JJ. et al. Inflammatory airway features and hypothalamic-pituitary-adrenal axis function in asthmatic rats combined with chronic obstructive pulmonary disease[J]. Chin med J.2010,123(13):1720-1726.
[5]Brass DM, Hollingsworth JW, Cinque M. et al. Chronic LPS inhalation causes emphysema-like changes in mouse lung that are associated with apoptosis[J]. Am J Respir Cell Mol Biol,2008,39(5):584-590.
[6]李素云,任伟宏,王明航,等.细菌感染诱导的COPD急性加重期大鼠模型炎症细胞的变化与意义[J].中国中医基础医学杂志.2009,15(6)：445-446.
[7]Tonio P, Reinoud G, Andries L, et al. Cigarette smoke and lipopolysaccharide induce a proliferative airway smooth muscle phenotype[J]. Respir Res.2010,11(1):48.
[8]Xu L, Cai BQ, Zhu YJ. Pathogenesis of cigarette smoke-induced chronic obstructive pulmonary disease and therapeutic effects of glucocorticoids and N-acetylcysteine in rats[J]. Chin med J,2004,117(11):1611-1619.
[9]MURARESCU ED, Eloae-Zugun F, Mihailovici MS. Experimental COPD induced by solid combustible burn smoke in rats:a study of the emphysematous changes of the pulmonary parenchyma[J]. Romanian Journal of Morphology and Embryology, 2008,49(4):495-505.
[10]MURARESCU ED, Iancu R, Mihailovici MS. Morphological changes positive correlates with oxidative stress in COPD. Preliminary data of an experimental rat model-study and literature review[J]. Rom J Morpholo Embryol,2007,48(1):59-65.
[11]Li MC, Li Q, Yang G, et al. Cold temperature induces mucin hypersecretion from normal human bronchial epithelial cells in vitro through a transient receptor potential melastatin 8(TRPM8)-mediated mechanism[J]. J Allergy Clin Immunol.2011,128(3): 626-634.
[12]Birrell MA, Wong S, Hele DJ, etal. Steroid-resistant inflammation in a rat model of chronic obstructive pulmonary disease is associated with a lack of nuclear factor-KB Pathway Activation[J]. Am J Respir Crit Care Med.2005,172(1):74-84.
[13]Tazaki G, Kondo T, Tajiri S, et al. Functional residual capacity and airway resistance in rats of COPD model induced by systemic hyaluronidase[J]. Tokai J Exp Clin Med. 2006,31(3):115-117.
[14]Zhang XJ, Zheng HG, Ma WJ, et al. Tryptase enzyme activity is correlated with severity of chronic obstructive pulmonary disease[J]. Tohoku J. EXP Med,2011, 224(3),179-187.
[15]Wong S, Belvisi MG, Birrell MA. MMP/TIMP expression profiles in distinct lung disease models:implications for possible future therapies[J]. Respir Res,2009, 10(1):72.
[16]Fermosellea C, Sancheza F, Barreiro E. Reduction of muscle mass mediated by myostatin in an experimental model of pulmonary emphysema[J]. Arch Bronconeumol,2011,47(12):590-598.
[17]杨化强,赖良学.基因修饰猪作为人类疾病模型的研究进展[J].科技导报.2011.29(30)：57-62.
[18]Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function[J]. Am Rev Resp Dis,1977, 115(2):195-205.
[19]Coultas DB, Hanis CL, Howard CA, et al. Heritability of ventilatory function in smoking and nonsmoking New Mexico Hispanics[J]. Am Rev Respir Dis,1991, 144(4):770-775.
[20]Misra RP, Duncan SA. Gene targeting in the mouse:advances in introduction of transgenes into the homologous recombination [J]. Endocrine,2002,19(3):229-238.
[21]Ishii Y, Itoh K, Morishima Y, et al. Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema [J]. Immunol,2005,175(10):6968-6975.
[22]Mohsenin A, Mi T, Xia Y, et al. Genetic removal of the A2A adenosine receptor enhances pulmonary inflammation, mucin production, and angiogenesis in adenosine deaminase-deficient mice[J]. Am J Physiol Lung Cell Mol Physiol.2007,293(3): L753-761.
[23]Rogana MP, Reznikov LR, Pezzulo AA, et al. Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1(IGF1)levels at birth[J]. Proc Natl Acad Sci USA,2010,107(47):20571-20575.
[24]Ganguly K, Stoeger T, Wesselkamper SC, et al. Candidate genes controlling pulmonary function in mice:transcript profiling and predicted protein structure[J]. Physiol Genomics.2007,31(3):410-21.
[25]曹国强,钱桂生,林莉,等.慢性阻塞性肺疾病大鼠肺组织细胞凋亡和增殖的变化,2005,28(3)：169-72.
[26]Sun T, Wang X, Liu Z, et al. Patterns of cytokine release and evolution of remote organs from proximal femur fracture in COPD rats[J]. Injury.2011,42(8):825-832.
[27]张永,杨绍容,程德云.泼尼松对IL-8在COPD大鼠肺组织表达的影响[J].四川大学学报(医学版),2007,38(2)：287-90.
[28]张葵,滕久祥,彭芝配.肺气虚证稳定期慢性阻塞性肺病大鼠模型的建立[J].中国中医基础医学杂志,2009,15(3)：179-181.
[29]刘蕾,李宇航,刘妙,等.熏烟叠加气管内滴注脂多糖致慢性阻塞性肺病大鼠动物模型基本证候判定[J].辽宁中医杂志,2011,38(12)：2348-2351.
[30]李素云,乔翠霞,李建生,等.慢性阻塞性肺疾病急性加重期痰湿证模型的建立与评价[J].中华中医药杂志,2012,27(3)：585-590.
[31]Wood AM, Stockley RA. The genetics of chronic obstructive pulmonary disease[J]. Respiratory Research.2006,7(1):130.
[1]Weiss ST. What genes tell us about the pathogenesis of asthma and chronic obstructive pulmonary disease[J]. Am JRespirCrit CareMed,2010,81(11):1170-1173.
[2]Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Zhou Y, et al. Prevalence of chronic obstructive pulmonary disease in China:a large, population-based survey. Am J Respir Crit Care Med 2007;176:753-760.
[3]Buist AS, Mcburnie MA, Vollmer WM, et al. International variation in the prevalence of COPD(the BOLD study):A population-based prevalence study[J]. The lancet,2007,370(9589):741-750.
[4]Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways[J]. J Clin Invest,2002,109(5):571-577.
[5]陈淑靖,白春学.气道黏液中粘蛋白MUC5AC研究进展[J].中华结核和呼吸杂志,2007,30(6)：46 1-463.
[6]Middleton PG, Pollard KA, Wheatley JR. Hypertonic saline alters ion transport across the human airway epithelium[J]. Eur Respir J,2001,17(2):195-199.
[7]Mall MA. Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction:Lessons from mouse models[J]. J Aerosol Med Pulm Drug Deliv,2008, 21(1):13-24.
[8]Jayaraman S, Joo NS, Reitz B, et al. Submucosal gland secretions in airways from cystic fibrosis patients have normal Na+and pH but elevated viscosity. Proc Natl Acad Sci USA,2001,98:8119.
[9]Moretti M, Bottrighi P, Dallari R, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease:the EQUALIFE Study[J]. Drugs Exp Clin Res,2004,30(4):143-152.
[10]Fahy JV. Goblet cell and mucin gene abnormalities in asthma[J]. Chest,2002,122(6 Suppl):320S.
[11]何燕霞,巨春荣,宋改芳,等.慢性阻塞性肺疾病大鼠气道炎症细胞及黏蛋白检测[J].郑州大学学报(医学版),2007,42(1)：126.
[12]王可.COPD的粘液分泌机制研究[D].2006四川大学临床医学博士专业学位论文
[13]Williams OW, Sharafkhaneh A, Kim V, Dickey BF, Evans CM. Airway mucus:from production to secretion. Am J Respir Cell Mol Biol 2006;34:527-526.
[14]周向东,童瑾,兰箭.性阻塞性肺疾病患者气道粘蛋白分子表型的研究[J]中华 结核和呼吸杂志,2002,7(25)：437-437.
[15]王晓龙,周向东.核转录因子-κB在慢性气道粘液高分泌大鼠肺组织中的表达及意义[J].中国呼吸机危重监护杂志,2004,3(3)：101-102.
[16]XIAO Jun, WANG Ke, FENG Yu-lin, et al Role of extracellular signal-regulated kinase 1/2 in cigarette smoke-induced mucus hypersecretion in a rat model Chinese Medical Journal 2011;124(20):3327-3333
[17]马睿,王颖,陈岗,等.COPD患者气道杯状细胞增生和粘蛋白表达量的变化[J].上海第二医科大学学报2004,24(12)：1031-1033
[18]Guoqing Wang, Zhibo Xu, Rui Wang, et al. Genes associated with MUC5AC expression in small airway epithelium of human smokers and nonsmokers[J]. BMC Medical Genomics 2012,5(21):doi:10.1186/1755-8794-5-21
[19]Peter Di Y, Jinming Zhao, Richart Harper. Cigarette smoke induces MUC5AC expression through the activation of Spl[J] JBC Papers in Press. Published on June 14,2012.
[20]Kirhams S, Sheehan J K, Knight D, et al. Heterogeneity of airways mucusrvariations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B[J]Bio chem,2002,361(Pt 3):537-546.
[21]杨宝学,赵雪俭.水通道蛋白的研究进展[J].中国病理生理杂志,2005,21(8)：1619-1622.
[22]祝小惠,钟相根,李宇航,等.COPD大鼠AQPs mRNA表达及“从肠论治”干预作用[J].中华中医药学刊,2011,29(1)：39-41.
[23]安宇,李学军.水通道蛋白-1在急性肾损伤中的作用[J].国际病理科学与临床杂志.2012,32(2)：180-184
[24]Borok Z, Verkman A S. Lung edema clearance:20 years of progress invited review:role of aquaporin, water channels in fluid transport in lung and airways[J]. J Appl Physiol,2002,93:2199-2206.
[25]Towne JE, Harrod KS, Krane CM, et al. Decreased expression of aquaporin (AQP)l and AQP5in mouse lung after acute viral infection[J]. Am J Respir Cell Mol Biol, 2000,22:34-44.
[26]张子强.水通道蛋白5促进肺癌增殖迁移及参与肺上皮屏障的作用和机制研究[D].复旦大学,2010：89.
[27]Verkman AS. Aquaporin water channels and endothelial cell function[J]. J Anat 2002;200:617-27.
[28]Jiao G, Li E, Yu R. Decreased expression of AQP1andAQP5 in acute injured lung in rats[J]. Chin Med J(Engl),2002,115(7):963.
[29]孙香蕾,张亮,吴硕,等.以AQP4表达诠释“肺液”与“肠津”于“肺病及肠”病理传变中的意义[J].中国中医急症,2012,21(4)：567-569.
[30]孙忠民,朱柏,杨岚,等.AQP4在COPD支气管黏膜的表达及其与患者肺功能、起到黏膜炎症的相关性[J].西安交通大学学报,2008,29(2)：193-195.
[31]高光洁,宋丹丹,张铁铮.肺组织AQP-1、AQP-4蛋白表达体外循环后肺上皮屏障功能障碍机制的探讨[J].现代预防医学,2011,38(12)：2357-2359.
[32]谢艳萍,陈才平,王建春,等.急性肺损伤大鼠肺水通道蛋白1和5的表达及功能的实验研究[J].中华结核和呼吸杂志,2005,28(6)：385-389.
[33]李波,陈东,王桂芳,等.水通道蛋白1、3、4、5在内毒素性急性肺损伤小鼠肺组织中的表达[J].第二军医大学学报,2008,29(2)：131-135.
[34]SongY, MaT, Matthay MA, etal. Role ofaquaporin-4 in air-space-to-capillary water permeability in intact mouse lung measured by a novel gravimetric method [J]. Gen Physiol,2000,115(1):17-27.
[35]Song Y, J ayaraman S, Yang B, etal. Role of aquaporin water channels in airway fluid transport, humidification, and surface liquid hydration[J]. J Gen Physiol.2001. 117(6):573-582.
[36]余保军,张文武.慢性阻塞性肺疾病急性发作期血浆VP、尿液中AQP2浓度变化研究[J].临床研究,2012,19(17)：33-34.
[37]Caramori G, Di Gregorio C, Carlstedt I, et al. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease[J]. Histopathology,2004, 45(5):477-484.
[38]Wang K, Feng YL, Wen FQ, et al. Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease[J]. Acta Pharmacol Sin,2007,28(8):1166-1174.
[39]董春玲,鲁继荣,王桂芳,等.哮喘小鼠肺组织中水通道蛋白5和黏蛋白5AC的表达变化及其相关性研究[J].中国现代医学杂志,2007,(24)：2961-2965,2970.
[40]Chen Z, Zhu R, Bai L, et al. Downregulation of aquaporin 5 induced by vector-based short hairpin RNA and its effect on MUC5AC gene expression in human airway submucosal gland cells[J]. Respir Physiol Neurobiol,2006,152(2):197-203.
[41]Wang K, Feng YL, Wen FQ, et al. Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease[J]. Acta Pharmacol Sin,2007,28(8):1166-1174.
[42]Wang K, Feng YL, Wen FQ, Chen XR, Ou XM, et al. (2007)Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease[J]. Acta Pharmacol Sin 28(8):1166-1174.
[43]Song Y, Verkmna AS. Aquaporin-5 dependent fluid secretion in airway submucosal glnads[J]. J Bio Chemist,2001,276:41288-41292.
[2]加孜那·托哈依,胡晓婷,赵双锁,等.新疆和田农村地区60岁以上维吾尔族人群慢性阻塞性肺病的流行病学调查[J].新疆医科大学学报,2010,33(9)：1017-1010.
[3]Buist AS, Mcburnie MA, Vollmer WM, et al. International variation in the prevalence of COPD(the BOLD study):A population-based prevalence study[J]. The lancet,2007,370(9589):741-750.
[4]宋一平,崔德健,茅培英.COPD大鼠模型的建立及药物干预的影响[J].中华内科杂志,2000,39：712-714.
[5]宋一平,崔德健,茅培英,等.COPD大鼠模型气道重塑及生长因子的研究[J].中华结核和呼吸杂志,2001 24：283-287.
[6]许浒,熊密,黄庆华.细菌感染导致慢性阻塞性肺病大鼠模型的探讨[J].中华结核和呼吸杂志,1 999,22(12)：739-742.
[7]郭庭杰.COPD患者肺内的透明质酸水平增高与肺功能和局部炎症的相关性[J].国外医学内科学分册,2006,33(2)：92.
[8]Priiss-ustunA, Corvalan C. Preventing Disease trough Healthy Environments. Towards an Estimate of the Environment Burden of Disease[M]. Geneva:Word Health Organization,2006:19.
[9]岳海燕,申双和.呼吸道和心脑血管疾病与气象条件关系的研究进展[J].气象与环境学报,2009,25(2)：57.
[10]Donaldson GC, Seemungal T, Jeffries DJ, et al. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease[J]. Eur Respir J, 1999,13(4):844-849.
[11]梁剑辉.冬春须防寒—认识低温对COPD的影响[J].澳门医疗与健康,2010,11(1)：11.
[12]Koskela H, Pihlajamaki J, Pekkarinen H, et al. Effect of cold air on exercise capacity in COPD:increase or decrease. Chest.1998,113(6):1560-1565.
[13]Miravitlles M, Ferrer M, Pont A, et al. Effect if exacerbations on quality if life in patients with chronic obstructive pulmonary disease:a 2 year follow up study. Thorax.2004,59(5):387-395.
[14]De la lglesia martine F, pellicer vazquz C, Ramos polledo V, et al. Chronic obstructive pulmonary disease and the season of the year, Arch Bronchoneumol, 2000,36(2):84-89.
[15]Koskela HO. Cold air-provoked respiratory symptoms:the mechanisms and management][J]. Int J Circumpolar Health,2007,66(2):91-100.
[16]Davis MS, Malayer JR, Vandeventer L, et al. Cold weather exercise and airway cytokine expression [J]. j Appl Physiol,2005,98(6):2132-2136.
[17]阴俊,谈建国,竺丽明,等.不同地区慢性阻塞性肺病与气象因子相关性分析[J].气象科技,2007,35(6)：843.
[18]殷涛.外燥伤肺的分子机制研究[D].湖北中医药大学,2011：9.
[19]王剑,徐志伟,严灿,等.从黏液类物质病理改变探讨痰证机理[J].上海中医药杂志,2005,39(10)：44.
[20]Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways[J]. J Clin Invest,2002,109(5):571-577.
[21]陈淑靖,白春学.气道黏液中粘蛋白MUC5AC研究进展[J].中华结核和呼吸杂志,2007,30(6)：461-463.
[22]Middleton PG, Pollard KA, Wheatley JR. Hypertonic saline alters ion transport across the human airway epithelium [J]. Eur Respir J,2001,17(2):195-199.
[23]Mall MA. Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction:Lessons from mouse models[J]. J Aerosol Med Pulm Drug Deliv,2008, 21(1):13-24.
[24]Jayaraman S, Joo NS, Reitz B, et al. Submucosal gland secretions in airways from cystic fibrosis patients have normal Na+and pH but elevated viscosity. Proc Natl Acad Sci USA,2001,98:8119.
[25]National Institute for Clinical Excellence(NICE). Chronic obstructive pulmonary disease:national clinical guideline on management of chronic abstructive pulmonary disease in adults in primary and secondary care. Thorax 2004,59.
[26]Moretti M, Bottrighi P, Dallari R, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease:the EQUALIFE Study[J]. Drugs Exp Clin Res,2004,30(4):143-152.
[27]Fahy JV. Goblet cell and mucin gene abnormalities in asthma[J]. Chest,2002, 122(6 Suppl):320S.
[28]何燕霞,巨春荣,宋改芳,等.慢性阻塞性肺病大鼠气道炎症细胞及黏蛋白检测[J].郑州大学学报(医学版),2007,42(1)：126.
[29]杨宝学,赵雪俭.水通道蛋白的研究进展[J].中国病理生理杂志,2005,21(8)：1619-1622.
[30]SaadounS, PaPadoPou}05MC, Hara-ChikumaM, etal:ImPairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature,2005, 434:786-92,
[31]Ruiz-EderraJ, VerkmanAS:AquaPorin-l-feeilitatedkeratoCyte migration in cell culture and in vivo corneal wound healing models. ExPEye Res2009,89:159-65.
[32]Borok Z, Verkman A S. Lung edema clearance:20 years of progress invited review:role of aquaporin, water channels in fluid transport in lung and airways[J]. J Appl Physiol,2002,93:2199-2206
[33]Shen Y, W ang YL, Chen ZH, et al. Role of aquaporin 5 in antigen-induced airway inflammation and mucous hyperproduction in mice[J]. J Cell Mol Med,2011, 15(6):1355-1363.
[34]Caramori G, Di Gregorio C, Carlstedt I, et al. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease[J]. Histopathology, 2004,45(5):477-484.
[35]Wang K, Feng YL, Wen FQ, et al. Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease[J]. Acta Pharmacol Sin,2007,28(8):1166-1174.
[36]董春玲,鲁继荣,王桂芳,等.哮喘小鼠肺组织中水通道蛋白5和黏蛋白5AC的表达变化及其相关性研究[J].中国现代医学杂志,2007,(24)：2961-2965,2970.
[37]Chen Z, Zhu R, Bai L, et al. Downregulation of aquaporin 5 induced by vector-based short hairpin RNA and its effect on MUC5AC gene expression in human airway submucosal gland cells[J]. Respir Physiol Neurobiol,2006,152(2): 197-203.
[38]Jiao G, Li E, Yu R. Decreased expression of AQP1 and AQP5 in acute injured lung in rats[J]. Chin Med J(Engl),2002,115(7):963.
[39]Towne JE, Harrod KS, Krane CM, et al. Decreased expression of aquaporin (AQP) land AQP5in mouse lung after acute viral infection[J]. Am J Respir Cell Mol Biol, 2000,22:34-44.
[40]张子强,水通道蛋白5促进肺癌增殖迁移及参与肺上皮屏障的作用和机制研究[D].复旦大学,2010：89.
[41]孙忠民,朱柏,杨岚,等.AQP4在COPD支气管黏膜的表达及其与患者肺功能 起到黏膜炎症的相关性[J].西安交通大学学报,2008,29(2)：193-195.
[42]祝小惠,钟相根,李宇航,等.“通利大肠”对COPD大鼠AQPs mRNA表达的影响及与气道炎症相关性研究[J].中华中医药杂志,2010,25(12)：2246-2249.
[43]胡利群,丁建中.水通道蛋白与肺部疾病研究进展[J].长江大学学报：自科版医学版,2008,5(4)：83-86.
[44]张六通,丁建中,王明明,等.外燥对小鼠肺组织水通道蛋白5表达的影响及意义[J].湖北中医学院学报,2010,12(1)：3-5.
[45]丁建中,尚荣,张燕翔,等.水通道蛋白4在外燥小鼠肺组织表达的实验研究[J].长江大学学报(自然科学版)2010,7(3)：2.
[46]张六通,丁建中,李军川,等.外燥对小鼠肺组织水通道蛋白5表达的影响及意义[J].湖北中医学院学报,2010,12(1)：3-5.
[47]高振,李风森,哈木拉提·吾甫尔,杨剑.慢性阻塞性肺病中医证治用药的性味及归经规律研究[J].中医药杂志(台湾),2010,21(3,4)：143-148.
[48]李风森,同立宏,荆晶,等.穴位贴敷治疗慢性阻塞性肺病稳定期选穴及用药规律研究[J].中国中医药信息杂志,2012,19(6)：24-27.
[49]中华医学会呼吸病学分会·慢性阻塞性肺病(COPD)诊治规范(草案).中华结核和呼吸杂志,1997,20(4)：199-203.
[50]中华医学会呼吸病学分会慢性阻塞性肺病学组.慢性阻塞性肺病诊治指南.中华结核和呼吸杂志,2002,25(8)：453-460.
[51]中华医学会呼吸病学分会慢性阻塞性肺病组.慢性阻塞性肺病诊治指南(2007年修订版).中华结核和呼吸杂志,2007,1(30)：8.
[52]GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2006, http://goldcopd. com/index. 2007-01-22.
[53]韩萍.四逆汤合小青龙汤加减治疗AECOPD疗效观察.皖南医学院学报,2010,29(1)：54-56.
[54]任明智.小青龙汤对慢性阻塞性肺病急性加重期的临床疗效观察.中国实用医药,2012,7(7)：129-130.
[55]钱旭红.小青龙汤治疗慢性阻塞性肺病发作期30例疗效分析.中国医药科学,2011,1(18)：73+80.
[56]杨荣源,林燕凤,李际强.小青龙汤加减治疗慢性阻塞性肺病急性加重期临床观察.新中医,2009,41(1)：43-44.
[57]李军林.小青龙汤治疗慢性阻塞性肺病发作期39例临床观察.基层医学论坛,2011,15(28)：943-944.
[58]韩萍.附子理中汤合小青龙汤加减治疗慢性阻塞性肺病急性加重期疗效观察.中国中医急症,2011,20(5)：694-695.
[59]王东.加味小青龙汤治疗痰浊阻肺型COPD急性加重期的临床疗效观察.广州中医药大学,2011：11-18.
[60]谢加富,陈仕章,秦平祥,曹锐彬,朱少惠,李颂梅,陈美英,张艳.小青龙汤配合基础治疗对慢性阻塞性肺病患者血氧饱和度的影响.临床和实验医学杂志,2008,7(9)：5-6.
[61]邹交平.丹参注射液合小青龙汤加减治疗慢性阻塞性肺病急性发作32例.安徽中医临床杂志,1999,11(3)：172.
[62]李旭.小青龙汤治疗慢性阻塞性肺病急性加重期39例临床观察.中医临床研究,2011,3(23)：41-43.
[63]赵军,金英.小青龙汤合血府逐瘀汤用于慢性阻塞性肺病发作期40例疗效观察.贵阳中医学院学报,2007,29(5)：19-20.
[64]谢加富,曹锐彬,陈仕章,秦平祥,朱少惠,李颂梅,陈美英,张艳.小青龙合剂配合基础治疗对慢性阻塞性肺病患者排痰效果的影响.实用医学杂志,2009,25(1)：144-146.
[65]方灵云.小青龙汤治疗COPD38例观察.浙江临床医学,2003,5(3)：217.
[66]韦金荣.小青龙汤加味治疗肺心病疗效观察.中医临床研究,2010,2(16)：77.
[67]葛长胜,高翠,闫培清,张华.小青龙汤联合无创通气治疗慢性阻塞性肺病合并呼吸衰竭36例.实用中医内科杂志,2010,(7)：33-35.
[68]钟勇.小青龙汤结合无创通气治疗慢性阻塞性肺病急性加重期30例的临床研究.时珍国医国药,2010,21(7)：1836-1837.
[69]孔祥建.小青龙汤雾化吸入对COPD急性加重期呼吸功能及血气的影响.湖南中医杂志,2010,26(4)：19-20.
[70]徐新毅,周洵,刘炜,等.止咳平喘膏穴位敷贴配合西药治疗慢性阻塞性肺病36例临床研究[J].贵阳中医学院学报,2005,27(2)：38～40.
[71]郑彩霞,王洪刚,刘振安.穴位贴敷为主治疗慢性阻塞性肺病90例[J].中医研究,2005,18(10)：36～37.
[72]徐艳玲,赵克明,曲妮妮,等.中药涌泉穴位贴敷治疗慢性阻塞性肺病稳定期的临床研究[J].辽宁中医杂志,2008,35(7)：1055～1056.
[73]王海峰,李素云,王明航,等.中药穴位贴敷治疗慢性阻塞性肺病患者临床观察及免疫功能的影响[J].中华中医药学刊,2009,27(6)：1209～1211.
[74]关秋红,武维屏,田秀英,等.益气活血化痰贴防治慢性阻塞性肺病临床观察[J].中国中医药信息杂志,2009,16(11)：60～61.
[75]石克华,折哲,熊必丹,等.咳喘散穴位敷贴治疗慢性阻塞性肺病稳定期临床疗效观察[J].世界中西医结合杂志,2009,4(3)：195～197.
[76]朱晓龙.中药“穴位贴敷”治疗慢性阻塞性肺病肺肾气虚型患者临床疗效观察[D].贵阳中医学院,2010：19-26.
[77]阚竞.中药三伏贴治疗慢性阻塞性肺病稳定期(肺肾气虚型)的临床观察[D].湖北中医药大学,2010：3-11.
[78]刘斌,李英姿,黄大文.中药穴位敷贴对慢性阻塞性肺病免疫球蛋白及C反应蛋白的影响[J].湖北中医杂志,2010,32(12)：7～8.
[79]邓莉,徐艳玲.中药涌泉穴贴敷治疗慢性阻塞性肺病及护理[J].实用中医内科杂志,2010,25(3)：41～42.
[80]夏令琼,廖色青,梁云花,等.中药敷贴治疗慢性阻塞性肺病稳定期临床观察及护理[J].齐齐哈尔医学院学报,2010,31(16)：2657～2658.
[81]潘继红,黄玮.“伏九”穴位贴敷对慢性阻塞性肺病患者免疫功能影响的临床研究[J].中医药导报,2011,17(6)：68～70.
[82]谭光波,柏正平,胡学军.冬病夏治敷贴疗法对COPD稳定期患者生活质量的影响[C].全国中西医结合防治呼吸系统疾病学术研讨会论文集》浙江·杭州：2009：77-80.
[83]毕蓉蓉,张惠勇,耿佩华,等.冬病夏治穴位疗法对慢性阻塞性肺病患者肺通气功能的影响[J].上海中医药大学学报,2011,25(3)：32～35.
[84]杨耀忠,郭美珠,梁薇,等.穴位敷贴治疗慢性阻塞性肺病稳定期临床研究[J].辽宁中医杂志,2011,38(6)：1192～1194.
[85]王兰娣.中药穴位贴敷联合补肺益寿合剂治疗慢性阻塞性肺病71例[J].甘肃中医学院学报,2009,26(6)：33～35.
[86]王燕芳.补肺益肾方联合穴位贴敷对慢性阻塞性肺病稳定期的疗效评价及成本效果分析[D].河南中医学院,2010：8-25.
[87]张颖,高鹏飞,方忠宏,等.中药治疗慢性阻塞性肺病的疗效观察[J].上海中医药杂志,2004,38(6)：6～7.
[88]牟晓华,沈宁,邱梦茹.止咳平喘贴治疗慢性阻塞性肺病缓解期临床观察[J].中国中医药信息杂志,2009,16(12)：59～60.
[89]范春,周运海.三伏天穴位敷贴结合金水宝口服治疗肺肾两虚型COPD稳定期30例临床研究[J].江苏中医药,2011,43(7)：69～70.
[90]浦明之.穴位敷贴配合扶正胶囊治疗肺肾两虚型COPD稳定期疗效观察[J].山西中医,2010,26(4)：40～41.
[91]彭明松,龚新全,谢六安.中药穴位贴敷治疗慢性阻塞性肺病的临床观察[J]. 湖北中医杂志,2006,28(7)：44～45.
[92]宋昱晨.穴位贴敷与卡介苗素注射治疗稳定期慢性阻塞性肺病的疗效和免疫指标对比观察[J].浙江中医杂志,2008,43(8)：441-443.
[93]陈平,许光兰.益气补肺膏穴位敷贴治疗慢性阻塞性肺病缓解期33例[J].陕西中医,2009,30(8)：945～947.
[94]王海燕,郑连雪.穴位贴敷治疗慢性阻塞性肺病60例[J].中国中医药现代远程教育,2010,8(23)：33～34.
[95]郑菲,李国勤,边永君,等.内外合治法治疗慢性阻塞性肺病稳定期的疗效观察[J].中国中西医结合杂志,2010,30(4)：369～372.
[96]魏亚东,鱼涛,谢燕华,等.“冬病夏治”治疗慢性阻塞性肺病稳定期患者疗效观察[J].中华中医药杂志,201 1,26(2)：408～410.
[97]马敏敏,张惠勇,段晨霞,等.冬病夏治穴位疗法对稳定期脾肾阳虚型慢性阻塞性肺病患者肺功能及生存质量的影响[J].辽宁中医杂志2011,38(5)：923～927.
[98]李素云,李建生,余学庆,等.舒肺贴治疗慢性阻塞性肺病疗效观察[J].陕西中医,2009,30(4)：391～392.
[99]李国勤,王蕾,边永君,等.冬病夏治消喘膏穴位贴敷疗法治疗稳定期慢阻肺的多中心随机双盲安慰剂对照研究[C].中国北京：2010：152-157.
[100]Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias, dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA,1995,273(5):408-412.
[101]周铭心.西北燥证研究概述[J].上海中医药杂志,2005,39(11)：43-45.
[102]周仲英主编,中医内科学[M].北京：中国中医药出版社,2003.
[103]国家技术监督局.GB/T16751. 2-1997中医临床诊疗术语：证候部分[S].北京：中国标准出版社,1997.
[104]冷南方主编.中医证候辩治轨范[M].北京：人民卫生出版社：1889.
[105]李风森,高振.慢性阻塞性肺病寒燥型诊断标准(2011版)[J].新疆医科大学学报,2012,35(10)：1317,1322.
[106]北京中医学院中医系中医基础理论教研室编,濒湖脉学白话解[M].北京：人民卫生出版社,1973年第2版修订：69.
[107]北京中医学院中医系中医基础理论教研室编,濒湖脉学白话解[M].北京：人民卫生出版社,1973年第2版修订：49.
[108]张连文,袁世宏.隐结构模型与中医辨证研究[J].北京中医药大学学报,2006,29(6)：365-369.
[109]王天芳,张连文,赵燕,等.隐结构模型及其在中医证候研究中的应用[J].北京中医药大学学报,2009,32(8)：519-526.
[110]王洪图主编,普通高等教育中医类规划教材：《内经选读》[M].上海：上海科学技术出版社,1997：65.
[111]徐雯洁,王天芳,王智瑜,等.基于隐结构法的慢性阻塞性肺病稳定期常见证候要素研究[J]北京中医药大学学报,2011,34(2)：82-86.
[112]Kara M. Preparing nurses for tile global pandemic of chronic obstructive pulmonary disease[J]. J Nurs Scholarsh,2005,37(2):127-133.
[113]阚海东,陈秉衡,贾健.上海市大气污染与居民每日死亡关系的病例交叉研究[J].中华流行病学杂志2003,24(10)：864.
[114]李小芡,胡志,李守田,等.安徽农村不同居住环境对慢阻肺患病率的影响[J].中国农村卫生事业管理,2002,22(4)：46-48.
[115]孟紫强,胡敏,郭新彪,等.沙尘暴对人体健康影响的研究现状[J].中国公共卫生2003,19(4)：471.
[116]Kwaasi AA, ParharRS, al-Mohanna FA, etal. Aeroallergens and viable microbes in sandstorm dust, Potential triggers of allergic and nonallergic res Nonallergic respiratory ailments[J]. allergy,1998,53(3):255-265.
[117]李风森,高振,荆晶等.慢性阻塞性肺病寒燥型分布状况及临床特点[J],中国中医药信息杂志,2012,19(2)：1-4.
[118]Mahadeva R, Shapiro SD. Chronic obstructive pulmonary disease:experimental animal models of pulmonary emphysema[J]. Thorax,2002,57:908-914.
[119]宋小莲,王昌惠,白冲.脂多糖结合熏烟法和单纯熏烟法建立慢性阻塞性肺病大鼠模型的比较[J].第二军医大学学报,2010,31(3)：248.
[120]迟春花,何冰,汤秀英,等.烟草雾吸入导致慢阻肺机制的实验研究一大鼠Clara细胞结构及其分泌蛋白的变化[J].心肺血管病杂志,2000,19：224-227.
[121]Cendon SP, Battlehner C, Lorenzi Filho G, et al. Pulmonary emphysema induced by passive smoking:an experimental study in rats. Braz J Med Biol Res,1997, 30(10):1241-1247.
[122]曾祥伯,COPD模型大鼠骨骼肌细胞凋亡及Bcl-2、Bax表达的实验研究[D].中南大学,2008：4-9.
[123]孙圣华.TNF-α对COPD营养不良动物模型骨骼肌蛋白质分解代谢的影响及可能的机制[D].中南大学,2006：3-11.
[124]窦桂荣,林炳水,崔振环,等.TRI近交系大鼠不同鼠龄、体重、身长及尾长的动态变化[J].中国实验动物学杂志,1995,5(2)：88-90.
[125]何明,涂长春,黄起壬,等Lee's指数用于评价成年大鼠肥胖程度的探讨[J].中国临床药理学与治疗杂志,1997,2(3)：177-179.
[126]黄婷婷,邱小汕,沈振宇,等.孕期营养不良对子代大鼠胰岛素抵抗的影响[J].中华预防医学杂志,2004,38(3)：184.
[127]冉丕鑫,王辰,姚婉贞,等.体重指数与慢性阻塞性肺病及生活质量的关系[J].中华结核和呼吸杂志,2007,30(1)：18-22.
[128]顾宇彤,蔡映云,柳启沛,等.慢性阻塞性肺病缓解期患者营养状况及对呼吸肌力量的影响[J].中华内科杂志,1998,37(10)：685.
[129]林江涛.缓解期慢性阻塞性肺病患者的营养状态与营养治疗[J].中华结核和呼吸杂志,1996,19(5)：261.
[130]Celli B R, Cote C G, Marin J M, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease[J]. N Engl J Med,2004,350(10):1005-1012.
[131]马真,卓宋明,周路球,等.体重指数与慢性阻塞性肺病的相关性研究[J].现代预防医学,2011,38(12)：2418.
[132]王芸,陈霞.慢性阻塞性肺病急性发作期患者营养状况与预后相关性的临床观察[J].现代预防医学,2011,38(18)：3838.
[133]Kessler R, Faller M, Fourgaut G, et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir CritCare Med,1999,159(1):158-164
[134]Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1998,157(6 Ptl):1791-1797.
[135]Romain K, Michele F, GillesF, etal-Predictive factors ofhospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med,1999;159:158-64.
[136]SahebijamiH, SathianpitayakulE-Influence ofbodyweight on the severity of dyspnea in chronic obstructive pulmonary disease[J]. Am J Respir Care Med, 2000;161:886-90.
[137]Vibhuti A, Arif E, Deepak D, et al. Correlation of oxidative status with BMI and lung function in COPD. Clin Biochem,2007,40(13-14):958.
[138]夏廉博.医疗气象学：天气、气候对健康的影响[M].北京：知识出版社,1984：32-34.
[139]常静,张颖,毛兵,等.柴葛清热颗粒治疗急性上呼吸道感染风热证的双盲随 机对照临床试验[J].中西医结合学报,2007,5(2)：141-146.
[140]仝战旗,钱妍,林明雄,等.“防感1号”预防老年人反复上呼吸道感染的临床研究[J].中华医院感染学杂志,2006,16(9)：1004-1006.
[141]钱桂生.急性上呼吸道感染[J].高校保健医学研究与实践,2005,2(1)：4-5.
[142]Davis SS. Nasal vaccines[J]. Adv Drug Deliv Rev,2001,51(1-3):21-42.
[143]李风森,高振,荆晶,等.慢性阻塞性肺病寒燥型模型全身炎症反应状态研究[J].科技导报,2011,29(18)：65-68.
[144]黄河,慢性阻塞性肺病稳定期患者血清瘦素及IL-1β与营养状况、生活质量及肺功能关系的初步研究[D].山东大学,2006：24.
[145]邵洪波,吴厚生,倪赞明.SLE患者外周血单核细胞分泌IL-6和IgG的研究[J].中国免疫学杂志,1993,9(2)：121.
[146]侯静静,朱蕾.白介素-8与慢性阻塞性肺病[J].国外医学：呼吸系统分册,2005,25(6)：427-429.
[147]周立新,陈凤娥,张秀平,等.白细胞介素-10在慢性阻塞性肺病患者血清中的表达及意义[J].数理医药学杂志,2000,13(6)：499-500.
[148]Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med,1995;152:1666-1672.
[149]Finlay GA, O'Driscoll LR, Russell KJ, D'Arcy EM, Masterson JB, FitzGerald MX, O'Connor CM. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997; 156:240-247.
[150]Bode W., Fernandez-Catalan C., Grams F, et al. Insights into MMP-TIMP Interactions. Ann. NY Acad. Sci.,1999,878:73-91.
[151]Hautamaki, RD, Kobayashi, DK, Senior, RM Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997;277,2002-2004.
[152]Morris, DG, Huang, X, Kaminsky, N, et al Loss of integrin alpha(v)beta6-mediated TGFβ activation causes MMP-12 dependent emphysema. Nature 2003;22, 169-173.
[153]Imai, K, Dalal, SS, Chen, E, et al Human collagenase(matrix metalloproteinase-1) expression in the lung of patients with emphysema. Am J Respir Crit Care Med 2001;163,786-791.
[154]Russell, RE, Culpitt, SV, Dematos, C, et al Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002;26,602-609.
[155]Segura-Valdez, L, Pardo, A, Gaxiola, M, et al Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000; 117,684-694.
[156]Ohnishi, K, Takagi, M, Kurokawa, Y, et al Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998;78,1077-1087.
[157]Cataldo D, Munaut C, Noe A, et al MMP-2-and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2000; 123,259-267.
[158]Vignola, AM, Riccobono, L, Mirabella, A, et al Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998; 158,1945-1950.
[159]Culpitt, S, Rogers, D, Traves, S, et al Sputum matrix metalloproteases:comparison between chronic obstructive pulmonary disease and asthma. Respir Med 2005;99, 703-710.
[160]Vignola, AM, Paganin, F, Capieu, L, et al Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J 2004;24,910-917.
[161]Vernooy, JH, Lindeman, JH, Jacobs, JA, et al Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004; 126,1802-1810.
[162]Betsuyaku, T, Nishimura, M, Takeyabu, K, et al Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med 1999;159,1985-1991.
[163]Finlay, GA, O'Driscoll, LR, Russell, KJ Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997; 156,240-247.
[164]Vignola, AM, Paganin, F, Capieu, L, et al Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J 2004;24,910-917.
[165]Madri, JA, Graesser, D, Haas, T The roles of adhesion molecules and proteinases in lymphocyte transendothelial migration. Biochem Cell Biol 1996;74,749-757.
[166]Chung, A, Gao, Q, Kao, WJ Macrophage matrix metalloproteinase-2/-9 gene and protein expression following adhesion to ECM-derived multifunctional matrices via integrin complexation. Biomaterials 2007;28,285-298.
[167]Masumoto, K, de Rooij, D, Suita, S, et al Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases during normal human pulmonary development. Histopathology 2005;47,410-419.
[168]Johnson, S, Knox, A Autocrine production of matrix metalloproteinase-2 is required for human airway smooth muscle proliferation. Am J Physiol 1999;277,L1109-L1117.
[169]Imai K, DalalSS, Chen ES, et al. Human collagenase(matrix metalloproteinase-1) expression in the lungs of patients with emphysema[J]. Am J Respir Crit Care Med, 2001,163:786-791.
[170]辛建保,胡道松,向敏,等.基质金属蛋白酶在肺气肿兔肺组织中的表达[J].中华结核和呼吸杂志,1999,22(6)：364.
[171]Selman M, Montano M, Ramos C, et al. Tobacco smoke-induced lung emphysema in guinea pigs is associated with increased interstitial collagenase[J]. Am J Physiol[J].1996,271:L734-L743.
[172]D Armiento J, Dalal SS, Okada Y, et al. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema[J]. Cell,1992,71:955-961.
[173]Bosse M., Chakir J, Rouabhia M, et al. Serum matrix metalloproteinase-9:Tissue inhibitor of matelloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. AM J Respir Crit Care Med,1999,159:596-602.
[174]Antonio M, Viguola, Loredana Riccobono, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinanse-1 ratio correlates with airflow obstruction in asthma and chronic bronchitism[J]. Am J Respir Care Med.,1998,158:1945-1950.
[175]Jerome pugin, Marie-Claude Widmer, Sylvie Kossodo, et al. Human neutrophils secrete gelatinase B in citro and in vivo in response to endotoxin and proinflammation mediators[J]. Am J Respir Cell Mol Biol,1999,20:458-464.
[176]Sam Lim, Nicolas Roche, Brian G. Oliver, Waldo Mattos, et al. Balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 from alveolar macrophages in cigarette smokers[J]. Am J Respir Care Med.,2000,162:1355-1360.
[177]Lourdes Segura-Valdez, Annte Pardo, Miguel Gaxiola, et al. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD[J]. Chese,2000,117:684-694.
[178]Wang Z, Zheng T, Zhu Z, Homer RJ, Riese RJ, Chapman HA Jr, Shapiro SD, Elias JA. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med 2000;192:1587-1600.
[179]Wert SE, Yoshida M, LeVine AM, Ikegami M, Jones T, Ross GF, Fisher JH, Korfhagen TR, Whitsett JA. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc Natl Acad Sci USA 2000;97:5972-5977.
[180]Selman M, Cisneros-Lira J, Gaxiola M, Ramirez R, Kudlacz EM, Mitchell PG, Pardo A. Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in Guinea pigs. Chest 2003;123:1633-1641.
[181]Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Gera L, Tuder RM, Voelkel NF. Methylprednisolone causes matrix metalloproteinase-dependent emphysema in adult rats. Am J Respir Crit Care Med2003;167:1516-1521.
[182]Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, Shim TS, Kim SE, Lee YS, Lee SD. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med,2005;172:987-993.
[183]Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT. Matrix metal loproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998;78:1077-1087.
[184]Mao JT, Tashkin DP, Belloni PN, Baileyhealy I, Baratelli F, Roth MD. All-trans retinoic acid modulates the balance of matrix metallo-proteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. Chest 2003; 124:1724-1732.
[185]Beeh KM, Beier J, Kornmann O, Buhl R. Sputum matrix metallo-proteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 2003;97:634-639.
[186]Russell RE, Thorley A, Culpitt SV, Dodd S, Donnelly LE, Demattos C, Fitzgerald M, Barnes PJ. Alveolar macrophage-mediated elastolysis:roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol 2002;283:L867-L873.
[187]Montano M, Beccerril C, Ruiz V, Ramos C, Sansores RH, Gonzalez-Avila G. Matrix metalloproteinases activity in COPD associated with wood smoke. Chest 2004;125:466-472.
[188]Foronjy R, Nkyimbeng T, Wallace A, Thankachen J, Okada Y, Lemaitre V, D'Armiento J. Transgenic expression of matrix metalloproteinase-9causes adult-onset emphysema in mice associated with the loss of alveolar elastin. Am J Physiol Lung Cell Mol Physiol 2008;294:L1149-L1157.
[189]Murphy G, Docherty A. The matrix metalloproteinases and their inhibitors[J]. Am J Respir Cell Mol Biol,1992,7:120-125.
[190]Mautino G, Oliver N, Chanez P, et al. Increased release of matrix metallo-proteinases-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics[J]. Am J Respir Cell Mol Biol.1997,17(5):583-91.
[191]Yao PM, Lemjabbar H, Dortho mp, et al. Balance between MMP-9 and TIMP-1 expressed by human bronchial epithelial cells:relevance to asthma[J]. Ann N Y Acad Sci.1999,30;878:512-514.
[192]Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003;28:12-24.
[193]Bosse M., Chakir J, Rouabhia M, et al. Serum matrix metalloproteinase-9:Tissue inhibitor of matelloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. AM J Respir Crit Care Med,1999,159:596-602.
[194]Culpitt SV, Rogers DF, Traves SL, Barnes PJ, Donnelly LE:Sputum matrix metalloproteases:comparison between chronic obstructive pulmonary disease and asthma. Respir Med 2005,99:703-710.
[195]Vernooy JH, Lindeman JH, Jacobs JA, Hanemaaijer R, Wouters EF:Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004,126:1802-1810.
[196]高振,阿地力江,哈木拉提.吾甫尔.寒燥型证候模型免疫功能紊乱的研究[J].中华中医药杂志,2010,25(8)：1227.
[197]高振,胡汉华,刘莹莹,等.寒燥型证候模型下丘脑-垂体-肾上腺轴紊乱状态研究[J].中医杂志,2010,51(10)：929.
[198]高振,阿地力江·阿布力米提,哈木拉提·吾甫尔.干燥寒冷环境对小鼠生物表征的影响[J].科技导报,2008,26(14)：84-87.
[199]尚德阳.瘀血与骨质疏松症的关系研究[J].辽宁中医药大学学报,2008,10(9)：41.
[200]Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bonemineral density in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med,2004,70(12):1286-1293.
[201]Shane E, Silverberg SJ, Donovan D, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease[J]. Am J Med,1996,101(3):262-269.
[202]Iqbal F, Michaelson J, Thaler L, et al. Declining bone mass in men with chronic pulmonary disease:contribution of glucocorticoid treatment, body mass index, and gonadal function[J]. Chest,1999,116(6):1616-1624.
[203]Rifas L, Fausto A, Scott MJ, et al. Expression of metalloproteinase and tissue inhibitors of metalloproteinase in human osteoblast-like cells:differentiatiln is associated with repression of metalloproteinase biosynthesis[J]. Endocrinology, 1994,134(1):213-221.
[204]刘敬,许增禄,王计奎,等.绝经后骨质疏松I型胶原代谢的变化[J].解剖学报,2002,33(2)：166-169.
[205]Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease:molecular and cellular mechanisms. Eur Respir J 2003;22:672-688.
[206]钟南山.慢性阻塞性肺病在中国[J].中国实用内科杂志,2011,31(5)：321-322.
[207]Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD)Workshop Summary. Am J Respir Crit Care Med 2001;163:1256-1276.
[208]Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020:Global Burden of Disease Study. Lancet 1997;349:1498-1504.
[209]李风森,高振,荆晶,等.慢性阻塞性肺病西北寒燥正分布及临床特点[J].中国中医药信息杂志,2012,19(2)：22-24.
[210]Chrousos GP. Stress and disorders of the stress system[J]. Nat Rev Endocrinol, 2009,5(7):374-381.
[211]Finkelstein R, Ma HD, Ghezzo H, et al. Morphometry of small airways in smokers and its relationship to emphysema type and hyperresponsiveness. Am J Respir Crit Care Medl995;152:267-76.
[212]Majo J, Ghezzo H, Cosio MG Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J2001;17:946-53.
[213]O'Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis:inverse relationship of CD8+T lymphocytes with FEV1. Am J Respir Crit Care Med1997;155:852-7.
[214]Saetta M, Di Stefano A, Turato G, et al. CD8+T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:822-6.
[215]Turato G, Zuin R,miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease:relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med2002; 166:105-10
[216]Baraldo S, Turato G, Badin C, et al. Neutrophilic infiltration within the airway smooth muscle in patients with COPD. Thorax2004;59:308-12.
[217]Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-30.
[218]Lowin B, Hahne M, Mattmann C, et al. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994;370:650-2.
[219]Syriala H, Surcel HM, Ilonea J. Low CD4/CD8 Lymphocyte ratio in acute myocardial infauction[J]. Clin Exp Immunol,1991,83(2):326-328.
[220]Peralbo E, Alonso C, Solana R. Invariant NKT and NKT-like lymphocytes:two different T cell subsets that are differentially affected by ageing[J]. Exp Gerontol, 2007,42(8):703-708.
[221]Turato G, Zuin R,miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease:relationship with lung function and radiologic emphysema [J]. Am J Respir Crit Care Med,2002,166(1):105-110.
[222]Casio MG, Majo J. Inflammation of the airways and lung parenchy main COPD:role of T cells [J]. Chest,2002,121(5 supply):160-165.
[223]Saetta M, Stefan AD. CD8+T-Lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med.1998;157: 822-6.
[224]Turato G, Zuin R, Seatta M. Pathogenesis and pathology of COPD. Respiration, 2001;68(2):117-28.
[225]王可.COPD的粘液分泌机制研究[D].四川大学博士学位论文,2006：1.
[226]Williams OW, Sharafkhaneh A, Kim V, Dickey BF, Evans CM. Airway mucus:from production to secretion. Am J Respir Cell Mol Biol 2006;34:527-526.
[227]周向东,童瑾,兰箭.性阻塞性肺疾病患者气道粘蛋白分子表型的研究[J]中华结核和呼吸杂志,2002,7(25)：437-437.
[228]祝小惠,钟相根,李宇航,等.COPD大鼠AQPs mRNA表达及“从肠论治”干预作用[J].中华中医药学刊,2011,29(1)：39-41.
[229]Verkman AS. Aquaporin water channels and endothelial cell function[J]. J Anat 2002;200:617-27.
[230]蒋力生,叶明花校注.喻嘉言医学三书·医门法律[M]北京：中医古籍出版社,2004：507.
[1]王彦,吴红英,李德冠,等.三个品系小鼠的遗传检测[J].中国辐射卫生,2010,19(1)：19-20.
[2]Prtather R S, Hawley R J, Carter D B, et al. Transgenic swine for biomedicine and agriculture[J]. Theriogenology,2003,59(1):115-123.
[3]Plopper CQ Hyde DM. The non-human primate as a model for studying COPD and asthma[J]. Pulm Pharmacol Ther. 2008,21 (5):755-766.
[4]Cai C, Zhang H, LE JJ. et al. Inflammatory airway features and hypothalamic-pituitary-adrenal axis function in asthmatic rats combined with chronic obstructive pulmonary disease[J]. Chin med J.2010,123(13):1720-1726.
[5]Brass DM, Hollingsworth JW, Cinque M. et al. Chronic LPS inhalation causes emphysema-like changes in mouse lung that are associated with apoptosis[J]. Am J Respir Cell Mol Biol,2008,39(5):584-590.
[6]李素云,任伟宏,王明航,等.细菌感染诱导的COPD急性加重期大鼠模型炎症细胞的变化与意义[J].中国中医基础医学杂志.2009,15(6)：445-446.
[7]Tonio P, Reinoud G, Andries L, et al. Cigarette smoke and lipopolysaccharide induce a proliferative airway smooth muscle phenotype[J]. Respir Res.2010,11(1):48.
[8]Xu L, Cai BQ, Zhu YJ. Pathogenesis of cigarette smoke-induced chronic obstructive pulmonary disease and therapeutic effects of glucocorticoids and N-acetylcysteine in rats[J]. Chin med J,2004,117(11):1611-1619.
[9]MURARESCU ED, Eloae-Zugun F, Mihailovici MS. Experimental COPD induced by solid combustible burn smoke in rats:a study of the emphysematous changes of the pulmonary parenchyma[J]. Romanian Journal of Morphology and Embryology, 2008,49(4):495-505.
[10]MURARESCU ED, Iancu R, Mihailovici MS. Morphological changes positive correlates with oxidative stress in COPD. Preliminary data of an experimental rat model-study and literature review[J]. Rom J Morpholo Embryol,2007,48(1):59-65.
[11]Li MC, Li Q, Yang G, et al. Cold temperature induces mucin hypersecretion from normal human bronchial epithelial cells in vitro through a transient receptor potential melastatin 8(TRPM8)-mediated mechanism[J]. J Allergy Clin Immunol.2011,128(3): 626-634.
[12]Birrell MA, Wong S, Hele DJ, etal. Steroid-resistant inflammation in a rat model of chronic obstructive pulmonary disease is associated with a lack of nuclear factor-KB Pathway Activation[J]. Am J Respir Crit Care Med.2005,172(1):74-84.
[13]Tazaki G, Kondo T, Tajiri S, et al. Functional residual capacity and airway resistance in rats of COPD model induced by systemic hyaluronidase[J]. Tokai J Exp Clin Med. 2006,31(3):115-117.
[14]Zhang XJ, Zheng HG, Ma WJ, et al. Tryptase enzyme activity is correlated with severity of chronic obstructive pulmonary disease[J]. Tohoku J. EXP Med,2011, 224(3),179-187.
[15]Wong S, Belvisi MG, Birrell MA. MMP/TIMP expression profiles in distinct lung disease models:implications for possible future therapies[J]. Respir Res,2009, 10(1):72.
[16]Fermosellea C, Sancheza F, Barreiro E. Reduction of muscle mass mediated by myostatin in an experimental model of pulmonary emphysema[J]. Arch Bronconeumol,2011,47(12):590-598.
[17]杨化强,赖良学.基因修饰猪作为人类疾病模型的研究进展[J].科技导报.2011.29(30)：57-62.
[18]Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function[J]. Am Rev Resp Dis,1977, 115(2):195-205.
[19]Coultas DB, Hanis CL, Howard CA, et al. Heritability of ventilatory function in smoking and nonsmoking New Mexico Hispanics[J]. Am Rev Respir Dis,1991, 144(4):770-775.
[20]Misra RP, Duncan SA. Gene targeting in the mouse:advances in introduction of transgenes into the homologous recombination [J]. Endocrine,2002,19(3):229-238.
[21]Ishii Y, Itoh K, Morishima Y, et al. Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema [J]. Immunol,2005,175(10):6968-6975.
[22]Mohsenin A, Mi T, Xia Y, et al. Genetic removal of the A2A adenosine receptor enhances pulmonary inflammation, mucin production, and angiogenesis in adenosine deaminase-deficient mice[J]. Am J Physiol Lung Cell Mol Physiol.2007,293(3): L753-761.
[23]Rogana MP, Reznikov LR, Pezzulo AA, et al. Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1(IGF1)levels at birth[J]. Proc Natl Acad Sci USA,2010,107(47):20571-20575.
[24]Ganguly K, Stoeger T, Wesselkamper SC, et al. Candidate genes controlling pulmonary function in mice:transcript profiling and predicted protein structure[J]. Physiol Genomics.2007,31(3):410-21.
[25]曹国强,钱桂生,林莉,等.慢性阻塞性肺疾病大鼠肺组织细胞凋亡和增殖的变化,2005,28(3)：169-72.
[26]Sun T, Wang X, Liu Z, et al. Patterns of cytokine release and evolution of remote organs from proximal femur fracture in COPD rats[J]. Injury.2011,42(8):825-832.
[27]张永,杨绍容,程德云.泼尼松对IL-8在COPD大鼠肺组织表达的影响[J].四川大学学报(医学版),2007,38(2)：287-90.
[28]张葵,滕久祥,彭芝配.肺气虚证稳定期慢性阻塞性肺病大鼠模型的建立[J].中国中医基础医学杂志,2009,15(3)：179-181.
[29]刘蕾,李宇航,刘妙,等.熏烟叠加气管内滴注脂多糖致慢性阻塞性肺病大鼠动物模型基本证候判定[J].辽宁中医杂志,2011,38(12)：2348-2351.
[30]李素云,乔翠霞,李建生,等.慢性阻塞性肺疾病急性加重期痰湿证模型的建立与评价[J].中华中医药杂志,2012,27(3)：585-590.
[31]Wood AM, Stockley RA. The genetics of chronic obstructive pulmonary disease[J]. Respiratory Research.2006,7(1):130.
[1]Weiss ST. What genes tell us about the pathogenesis of asthma and chronic obstructive pulmonary disease[J]. Am JRespirCrit CareMed,2010,81(11):1170-1173.
[2]Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Zhou Y, et al. Prevalence of chronic obstructive pulmonary disease in China:a large, population-based survey. Am J Respir Crit Care Med 2007;176:753-760.
[3]Buist AS, Mcburnie MA, Vollmer WM, et al. International variation in the prevalence of COPD(the BOLD study):A population-based prevalence study[J]. The lancet,2007,370(9589):741-750.
[4]Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways[J]. J Clin Invest,2002,109(5):571-577.
[5]陈淑靖,白春学.气道黏液中粘蛋白MUC5AC研究进展[J].中华结核和呼吸杂志,2007,30(6)：46 1-463.
[6]Middleton PG, Pollard KA, Wheatley JR. Hypertonic saline alters ion transport across the human airway epithelium[J]. Eur Respir J,2001,17(2):195-199.
[7]Mall MA. Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction:Lessons from mouse models[J]. J Aerosol Med Pulm Drug Deliv,2008, 21(1):13-24.
[8]Jayaraman S, Joo NS, Reitz B, et al. Submucosal gland secretions in airways from cystic fibrosis patients have normal Na+and pH but elevated viscosity. Proc Natl Acad Sci USA,2001,98:8119.
[9]Moretti M, Bottrighi P, Dallari R, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease:the EQUALIFE Study[J]. Drugs Exp Clin Res,2004,30(4):143-152.
[10]Fahy JV. Goblet cell and mucin gene abnormalities in asthma[J]. Chest,2002,122(6 Suppl):320S.
[11]何燕霞,巨春荣,宋改芳,等.慢性阻塞性肺疾病大鼠气道炎症细胞及黏蛋白检测[J].郑州大学学报(医学版),2007,42(1)：126.
[12]王可.COPD的粘液分泌机制研究[D].2006四川大学临床医学博士专业学位论文
[13]Williams OW, Sharafkhaneh A, Kim V, Dickey BF, Evans CM. Airway mucus:from production to secretion. Am J Respir Cell Mol Biol 2006;34:527-526.
[14]周向东,童瑾,兰箭.性阻塞性肺疾病患者气道粘蛋白分子表型的研究[J]中华 结核和呼吸杂志,2002,7(25)：437-437.
[15]王晓龙,周向东.核转录因子-κB在慢性气道粘液高分泌大鼠肺组织中的表达及意义[J].中国呼吸机危重监护杂志,2004,3(3)：101-102.
[16]XIAO Jun, WANG Ke, FENG Yu-lin, et al Role of extracellular signal-regulated kinase 1/2 in cigarette smoke-induced mucus hypersecretion in a rat model Chinese Medical Journal 2011;124(20):3327-3333
[17]马睿,王颖,陈岗,等.COPD患者气道杯状细胞增生和粘蛋白表达量的变化[J].上海第二医科大学学报2004,24(12)：1031-1033
[18]Guoqing Wang, Zhibo Xu, Rui Wang, et al. Genes associated with MUC5AC expression in small airway epithelium of human smokers and nonsmokers[J]. BMC Medical Genomics 2012,5(21):doi:10.1186/1755-8794-5-21
[19]Peter Di Y, Jinming Zhao, Richart Harper. Cigarette smoke induces MUC5AC expression through the activation of Spl[J] JBC Papers in Press. Published on June 14,2012.
[20]Kirhams S, Sheehan J K, Knight D, et al. Heterogeneity of airways mucusrvariations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B[J]Bio chem,2002,361(Pt 3):537-546.
[21]杨宝学,赵雪俭.水通道蛋白的研究进展[J].中国病理生理杂志,2005,21(8)：1619-1622.
[22]祝小惠,钟相根,李宇航,等.COPD大鼠AQPs mRNA表达及“从肠论治”干预作用[J].中华中医药学刊,2011,29(1)：39-41.
[23]安宇,李学军.水通道蛋白-1在急性肾损伤中的作用[J].国际病理科学与临床杂志.2012,32(2)：180-184
[24]Borok Z, Verkman A S. Lung edema clearance:20 years of progress invited review:role of aquaporin, water channels in fluid transport in lung and airways[J]. J Appl Physiol,2002,93:2199-2206.
[25]Towne JE, Harrod KS, Krane CM, et al. Decreased expression of aquaporin (AQP)l and AQP5in mouse lung after acute viral infection[J]. Am J Respir Cell Mol Biol, 2000,22:34-44.
[26]张子强.水通道蛋白5促进肺癌增殖迁移及参与肺上皮屏障的作用和机制研究[D].复旦大学,2010：89.
[27]Verkman AS. Aquaporin water channels and endothelial cell function[J]. J Anat 2002;200:617-27.
[28]Jiao G, Li E, Yu R. Decreased expression of AQP1andAQP5 in acute injured lung in rats[J]. Chin Med J(Engl),2002,115(7):963.
[29]孙香蕾,张亮,吴硕,等.以AQP4表达诠释“肺液”与“肠津”于“肺病及肠”病理传变中的意义[J].中国中医急症,2012,21(4)：567-569.
[30]孙忠民,朱柏,杨岚,等.AQP4在COPD支气管黏膜的表达及其与患者肺功能、起到黏膜炎症的相关性[J].西安交通大学学报,2008,29(2)：193-195.
[31]高光洁,宋丹丹,张铁铮.肺组织AQP-1、AQP-4蛋白表达体外循环后肺上皮屏障功能障碍机制的探讨[J].现代预防医学,2011,38(12)：2357-2359.
[32]谢艳萍,陈才平,王建春,等.急性肺损伤大鼠肺水通道蛋白1和5的表达及功能的实验研究[J].中华结核和呼吸杂志,2005,28(6)：385-389.
[33]李波,陈东,王桂芳,等.水通道蛋白1、3、4、5在内毒素性急性肺损伤小鼠肺组织中的表达[J].第二军医大学学报,2008,29(2)：131-135.
[34]SongY, MaT, Matthay MA, etal. Role ofaquaporin-4 in air-space-to-capillary water permeability in intact mouse lung measured by a novel gravimetric method [J]. Gen Physiol,2000,115(1):17-27.
[35]Song Y, J ayaraman S, Yang B, etal. Role of aquaporin water channels in airway fluid transport, humidification, and surface liquid hydration[J]. J Gen Physiol.2001. 117(6):573-582.
[36]余保军,张文武.慢性阻塞性肺疾病急性发作期血浆VP、尿液中AQP2浓度变化研究[J].临床研究,2012,19(17)：33-34.
[37]Caramori G, Di Gregorio C, Carlstedt I, et al. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease[J]. Histopathology,2004, 45(5):477-484.
[38]Wang K, Feng YL, Wen FQ, et al. Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease[J]. Acta Pharmacol Sin,2007,28(8):1166-1174.
[39]董春玲,鲁继荣,王桂芳,等.哮喘小鼠肺组织中水通道蛋白5和黏蛋白5AC的表达变化及其相关性研究[J].中国现代医学杂志,2007,(24)：2961-2965,2970.
[40]Chen Z, Zhu R, Bai L, et al. Downregulation of aquaporin 5 induced by vector-based short hairpin RNA and its effect on MUC5AC gene expression in human airway submucosal gland cells[J]. Respir Physiol Neurobiol,2006,152(2):197-203.
[41]Wang K, Feng YL, Wen FQ, et al. Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease[J]. Acta Pharmacol Sin,2007,28(8):1166-1174.
[42]Wang K, Feng YL, Wen FQ, Chen XR, Ou XM, et al. (2007)Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease[J]. Acta Pharmacol Sin 28(8):1166-1174.
[43]Song Y, Verkmna AS. Aquaporin-5 dependent fluid secretion in airway submucosal glnads[J]. J Bio Chemist,2001,276:41288-41292.